Subject Index

Abbreviations
AD - Alzheimer’s disease
APP - amyloid precursor protein
DLB - dementia with Lewy bodies
DTI - diffusion tensor imaging
FAST - Functional Assessment Staging
FTD - frontotemporal dementia
GDS - Global Deterioration Scale
LBD - Lewy body dementias
MCI - mild cognitive impairment
MMSE - Mini Mental State Examination
MTL - medial temporal lobe
NAA - N-acetylaspartate
OCID - obsessive-compulsive disorder
PDD - Parkinson’s disease dementia
SSRIs - selective serotonin reuptake inhibitors (SSRIs)

Note: All index entries relate to older people and psychiatric disorders unless otherwise indicated. vs denotes differential diagnosis or comparisons.

10/66 Dementia Research Group
dementia criteria 204–205
dementia impact 722–723
dementia prevalence in low-/middle-income countries 720, 721, 722
South Asia 730
impact of care in South Asia 731
physical/mental contribution to disability 722–723
14-3-3 protein 374
abdomen, examination 119
abdominal pain, examination 119
absorption, drugs 55, 537, 679
abuse, of older people see elder abuse accidents, fatal, bereavement considerations 556
accommodation (housing), concerns, suicidal behaviour 561
accommodation (ocular), assessment 120
Accountable Care Organizations 773
Accreditation Council for Graduate Medical Education (ACGME) review of training program structure 858
training program requirements 857–858
ACE see Addenbrooke’s Cognitive Examination (ACE)
ACE inhibitors, lithium interactions 581
N-acetylaspartate (NAA) see NAA
(N-acetylaspartate), magnetic resonance spectroscopy
acetylcholine (ACh) insufficiency, delirium pathophysiology 196, 197
precursors, therapeutic use 304
receptors, reduced in AD 296
reduced, Alzheimer’s disease 295, 299, 304
synthesis, reduced in AD 295
acetylcholinesterase inhibitors cardiac effects 125, 305
in learning disability 690
reversible 304, 305
use in China 738
in vascular dementia with AD 345
see also cholinesterase inhibitors acetyl-L-carnitine (ALCAR) 450
acquisitive offending 695
active life expectancy 67
ACTIVE (Advanced Cognitive Training for Independent and Vital Elderly) study 398, 399
activities in AD management 325
in care homes/NHS continuing care 761
lacking in care homes 79, 80
scheduling in CBT 544
activities of daily living (ADL) 177
alcohol abuse effect 675
assessment of needs 761
disability prevalence 66–67
psychiatric history-taking 111, 130
diagnostic feature 612
support in NHS continuing care 761
see also functional abilities; life skills
actual performance 177
functional capacity vs 176
acupuncture
depression treatment (China) 739
memory improvement 405, 407, 738
acute stress reaction 612, 640–641
clinical features and causes 640
differential diagnosis 640, 641–642
therapy 640–641
adaptation to functional decline 29
in successful ageing 71
adaptations/aids in rehabilitation 811
used in private psychiatric hospitals 796
adaptive plasticity 42, 43
Addenbrooke’s Cognitive Examination (ACE) 130–131, 132
ACE-R 130
language subtests 131–132
adenovirus-associated virus (AAV) 331, 336
adenohypophysis 45–47
adenosine, pharmacodynamics 58
adenoviral vectors 336
adjustment, after bereavement 557
adjustment disorder 510, 642
classification 642
clinical features 642
with depressed mood 459, 566
diagnostic feature 612
differential diagnosis, PTSD 641
stressful life events and 499, 642
treatment 642
adjustment reactions, long-term care placement 791–792
Administration on Aging (AoA) 421, 422
Admiral Nurse service 9, 811
α-2adrenoceptor agonist, delirium management 199
β-adrenoceptors
age-related reduced function 57–58
antagonists see beta-blockers
adenocortical axis, age-related changes 47
adrenocorticotropic hormone (ACTH) 47
adrenopause 47
ADRQL measure 187
adulthood, stages 650
adult stem cell niche 330, 332
see also neurogenic stem cell niche
advance care planning 840–841
advance decisions to refuse treatment (ADRTs) 841–842
advanced glycation endproducts (AGE) 271–272
advance directives 411, 769
instructional 411
advanced therapeutic technologies 334–338
advance patient statements 840
adverse drug reactions (ADR) 58
see also specific drug groups
advocacy service 852

Principles and Practice of Geriatric Psychiatry, 3rd edn. Edited by Mohammed T. Abou-Saleh, Cornelius Katona and Anand Kumar
© 2011 John Wiley & Sons, Ltd
affective disorders see bipolar disorder; depression; mania; mood disorders

Africa
cognitive impairment 735
dementia mortality 734
dementia prevalence 721, 734
demographics 734
depression prevalence 485, 486, 734
treatment of mental illness 735

age
dementia incidence, Lundby study 222, 223
as dementia risk factor 209, 238, 271
depression aetiology 617–618
AGECAT 174, 175, 617
cross-cultural validity of depression assessment 718
see also GMS-AGECAT
age discrimination 525
age discrimination

age
biological see biological ageing biomarkers 65
cellular and molecular effect 55
chronological 65
concepts 65
fear of 495
functional see functional ageing
global burden see demographics and ageing
‘intrinsic’/‘extrinsic’ factors affecting AD risk 271
normal see normal ageing
as physiological dynamic process 36
plasticity 65
statistics see demographics and ageing
successful see successful ageing
variability 65
whole of life approach 561

ageing biology
human syndromes elucidating 51–52
lower organism evidence 52–53

ageing theories
biological 51–52
medical model 61

ageism 565
age-related cognitive decline 209, 342
dementia vs 201, 209
tau tangles 259
see also normal ageing

aggressive behaviour 553
Alzheimer’s disease 229
during assistance with personal care 761, 762
benzodiazepines causing 627
in care homes 697
dementia 229, 695
forensic history-taking 112
management in NHS continuing care 762
see also behavioural disturbances

agitation
Alzheimer’s disease 229, 312
benzodiazepines causing 627
depression with dementia 553
management in ICU 199
see also delirium

agnosia, Alzheimer’s disease 227
agonists, drug 57
akathisia 702
albumin, drug binding 56, 679
alcohol
abstinence 667
age-related use decline 672, 674
benzodiazepine interactions 627, 682
cognitive performance and 676
daily amounts drunk 673
disability risk with 676
drug interactions 627, 665, 671, 680
effects in elderly 665–666, 671–672
heavy consumption see alcohol abuse,
heavy drinking
increased sensitivity in elderly 665–666, 671
light to moderate consumption 666, 667, 676
advantages, nutritional 826
neurotoxicity mechanism 378
outcomes associated with use 675–676
prevalence of use 672, 679
recommended limits 672
tolerance to 666
use in depression 675
vulnerability to toxicity of 665, 671
alcohol abuse 665–670
by abusers of elderly people 836
age/time of onset 666, 674
assessment and screening 673–674
by abusers of elderly people 836
assessment and screening 667, 673–674
benzodiazepine misuse with 681
causes/stressors 666, 674
clinical presentation 665, 666
crime associated 695
cultural aspects 668
definition of excessive drinking 673
detection/recognition 666–667, 673–674
failure to diagnose, reasons 673
detrimental effects 665–666, 671–672
DSM-IV 671
eyear-onset 666, 674
epidemiology 671–678
factors contributing to 666, 674
gender differences 672, 674
heavy drinking
factors associated 674
physical impairment 675
prevalence 672–673, 674
increased sensitivity in elderly 665–666, 671
late-onset 665, 666, 674
long-term remission 676
long-term solvent abuse synergism 380
loss of control in use 666
medical/geriatric admissions due to 673, 675
mild cognitive impairment 378, 379, 665
mood disorders due to 566, 675
mortality 666, 675
onset 666, 674–675
outcomes 675–676
paranoid delirium 600
physical conditions associated 665, 667, 675
prevalence 671–672
decline in use with age 672, 674
psychiatric co-morbidity 675
in psychiatric history-taking 111–112
rehabilitation 667
social decline 666–667
suicidal behaviour 560
thiamine deficiency synergistic action 379
treatment 667–668, 683
alcohol-deterrent medication 668
withdrawal management 667
symptoms 666
alcohol dependence 666
alcoholic dementia 378–380
neuropathogenesis 378
Alcoholics Anonymous 668, 683, 801
alcohol misuse see alcohol abuse
Alcohol Use Disorders Identification Test (AUDIT) 667
allostasis 47
allostatic load 47
alpha-2 adrenergic agonist, delirium
management 199
alpha rhythms in AD 38
decrease in ageing 38
in MCI 39

ALPHA study 213, 214
alpha synucleinopathies see Lewy body dementia spectrum
alprazolam 626
Alzheimer’s Association (AA) 422, 424
Alzheimer’s Caregiver Support Online 422, 424
Alzheimer’s disease (AD)
acupuncture effect 405
Addenbrooke’s Cognitive Assessment 131
advanced see Alzheimer’s disease (AD), severe
aetiology 723–724
affective disturbances 227–228
see also depression (geriatric)
aggression 229
agitation 229, 312
amyloid-related synaptic dysfunction before neuron loss 437
anaesthetics effect 821
antemortem markers 299–303
brain imaging 301
genomics and proteomics 301–302
neurochemistry and neurotransmitters 299–300
systemic pathology 300–301
apathetic syndrome (apathy) 230, 308
APOE*4 gene, risk with 210, 240, 723
see also apolipoprotein E allele e4 (APOE4)
appetite dysregulation 228–229, 826
atherosclerosis and 723
at-risk patients, AD-like functional patterns 29
autosomal dominant 240–244
behavioural disturbances 228, 229, 295, 312, 324
Alzheimer’s disease (AD) continued

management see behavioural management, in AD

see also under dementia; neuropsychiatric symptoms (non-cognitive)
biomarkers 205, 299–303
brain functional changes 29–30
brain regions affected 29
burden in China 737
burden on elderly caregivers 557
see also family caregivers, stress
caregivers see caregivers/carers; family caregivers
cholinergic deficit 295, 299, 304, 703, 821–822
classification 238
DSM-IV 107
DSM-IV-TR 201
ICD-10 106
clinical features 226–231, 238
affective features 227–228, 324
behavioural problems 229, 324
cognitive symptoms 226–227
non-cognitive neuropsychiatric 226, 227–229, 312
in people with learning disability 690, 691
psychotic disturbances 229–230, 312, 324
see also delusion(s); hallucinations
see also individual features above/below
cognitive assessment 131, 233
cognitive impairment 393
cognitive training, computer-assisted 398–399
common cause of death 176
complementary medicines effect see complementary and alternative medicine (CAM)
computational anatomy see computational anatomy, in AD
as a cortical dementia 233
cortical hyperexcitability 37–38
costs 271, 312, 421
cumulative lifetime risk 246
death, causes 238
deflurium with 226, 326–327
delusions see delusion(s)
dementia subtypes in 106
dementia with Lewy bodies (DLB) with 360
demoralization 228
depression in see depression (geriatric) diagnosis 345
clinical 238
criteria 137
disclosure, ethics 411
in Down syndrome 283–284
in long-term care 793
neuropathological 239–240
differential diagnosis 238–239
dementia with Lewy bodies (DLB) 365
depression 228

MCI 393
normal ageing changes 389, 393
personality disorders 657
using FDG-PET scans 259
using SPECT 258
vascular dementia 345
in Down syndrome see Down syndrome early-onset (EOAD) 238
early-onset familial (EOFAD) 240, 242, 246
early-onset (EOAD) vs late-onset (LOAD) cortical mapping 264
FDG-PET patterns 259
early stages
Clinical Dementia Rating (CDR) 172
exercise benefits 407
Global Deterioration Scale (GDS) 163, 164–166
memory impairment 226
EEG changes 38, 126
environmental factors 301, 723
epidemiology 208, 228
Lundby prevalence rates 222, 223
probability of contracting 222
race and gender affecting 246
see also Alzheimer’s disease (AD), prevalence
executive dysfunction 227, 393
executive dysfunction syndrome in 230 falls in 230, 763
familial (FAD) 252
molecular neuropathology 287–290
neurogenesis regulation 291
PS1 mutants 292
family history 238, 246
GDS/FAST and CDR scales 163, 166, 167
genes
APP gene mutations 127, 210, 240–242
location and inheritance 240
presenilins and 240–244
presenilin 2
see also amyloid precursor protein (APP); apolipoprotein E allele ε4 (APOE4); presenilin 1; presenilin 2
neurogenesis impairment 291
neuroimaging 301
neuronal loss
Functional Assessment Staging (FAST) and 166, 167
nucleus of Meynert 295
neuropsychiatric symptoms see neuropsychiatric symptoms (non-cognitive)
neuropsychological assessment see neuropsychological assessment pathogenesis 300–301
praxis 227
prediction of progression from MCI 30
prevalence 226, 238, 415, 719, 720
China 737
South Asia 730
USA 415, 421
prevention 205
prevention strategies 274–276, 723–724
diet and nutritional supplements 275
Ginkgo biloba 404
lifestyle factors 275–276
pharmacological 274–275
‘probable’, diagnosis 383
progression 226
[^18F]FDDNP-PET 264, 265
progressively lowered stress threshold 324
protein abnormalities 300
see also tau
as a proteinopathy (Aβ̂) 377
proteomic markers 302
regenerative medicine application 331
proteomic markers 302
severity assessment
treatment 304, 305
GDS/FAST and CDR scales 163
moradrenergic hyperactivity 163
PSEN1 mutations causing 242
treatment 304, 305
severity, Aβ̂ level associated 290
severity assessment
CDR stages 163, 170–173
FAST stages 163, 166, 167
GDS stages 163, 164–166
sleep disturbances 230, 703
spirituality and 742
sporadic
genes associated 244–245
genetics and risk factors 293
staging see dementia, staging
suicidal behaviour and 560, 561, 806
synaptic plasticity 37
temporal lobe atrophy 266, 267, 268
theories/models 324
time course 163
treatment alternative therapies/supplements 308–309
behavioural management see
behavioural management, in AD
in Down syndrome 284
effect on brain function 32
future therapies 309
pharmacological 304–311
regenerative medicine 331
see also cholinesterase inhibitors;
memantine
unmet needs model 324, 325
vascular dementia with 203, 208, 345
visuospatial deficits 39, 227, 393
without dementia 205
Alzheimer’s disease and related dementias (ADRD) see Alzheimer’s disease (AD);
dementia
Alzheimer’s Disease Anti-inflammatory Prevention Trial (ADAPT) 274
Alzheimer’s Disease Centers (ADCs) 422, 423
Alzheimer’s Disease China 738
Alzheimer’s Disease Cooperative Study (ADCS) 320, 421, 422, 423
Alzheimer’s Disease Education and Referral Center (ADERAR) 422, 423
Alzheimer’s Disease International 720, 721, 738
Alzheimer’s Disease Neuroimaging Initiative (ADNI) 262, 265, 268, 422, 423
Alzheimer’s disease societies (USA) 421–425
development 421
federal agencies 421–424
non-profit agencies 424
role and support from 421
Alzheimer’s Foundation of America (AFA) 422, 424
Alzheimer’s Reserach & Prevention Foundation (ARPFF) 422, 424
Alzheimer’s Society (UK) 759, 764, 814
ambulatory psychiatric care 777–784
American Association of Geriatric Psychiatry (AAGP) 774
geriatric psychiatrist number increase 858
American Federation for Aging Research (AFAR) 423, 425
amiodarone, elimination half-life 57
amitriptyline, depression in Parkinson’s disease 475
amnesia
complete generalized 643
dissociative 643
organic 643
see also memory impairment/deficits
AMPKines 297
amygdala
NAA increase in depression 449
volume reduction, recurrent depression 489
amyloid, cerebrovascular. [^11C]PIB-PET imaging 259
amyloid beta (Aβ̂) 239, 287
antibodies 253, 291
Aβ̂40 239, 240, 252, 281, 290
Aβ̂42 239, 240, 243, 252, 281, 290, 300
increased 241–242, 243
Aβ̂42 to Aβ̂40 ratio increased 240, 242, 243, 252, 290
β̂-sheet structure formation 287
binding to apoE 245
clearance 293
hypertension affecting 272
decreased in CSF, in AD 300
deposition
Alzheimer’s disease 239, 245, 265, 281, 291
Down syndrome 281
neuronal activity relationship 440
to 291
[^11F]FDDNP-PET imaging 259
formation from APP see amyloid precursor protein (APP)
formation prevention by α-secretase 290
glutamergic transmission reduction 296
increased levels 287, 290
AD severity association 290
increased reactive oxygen/nitrogen species due to 292–293
in Lewy body dementias 363
misfolding and oligomerization 290–291
anaesthetic agents causing 821
neurotoxicity prevention by antioxidants 293
role in AD 287–288
transgenic mouse models 252, 254–255, 291
vaccine, withdrawal 309
amyloid cascade hypothesis 252
amyloidosis, transgenic mouse models 252
amyloid beta (Aβ̂) 252, 254–255
amyloid plaques 218, 287
in Alzheimer’s disease 239
in Down syndrome 281
structure 239
amyloid precursor cleaving enzyme 1, β-site (BACE1) see BACE1
amyloid precursor-like protein 1 (APLP1) 287, 289
amyloid precursor-like protein 2 (APLP2) 287, 289
amyloid precursor protein (APP) 239, 287–290
Alzheimer’s disease genetics 240–242
APP gene 254
alternative splicing 241
function and expression 240–241
location and structure 240, 241
mapping 240, 241, 287
APP gene mutations 287–288, 301
Alzheimer’s disease 127, 210, 219, 240–242
inheritance and clinical features 240
L232P mutation 241–242
‘London’ mutations 241, 254
missemutations 240, 241
‘Swedish’ mutations 241, 252, 254, 290
V717F mutation 252
V717I mutation 241
C83 peptide 239

SUBJECT INDEX

869

in OCD 634
pharmacokinetics 625
starting doses 625
apathy 499
Alzheimer’s disease 230
cholinesterase inhibitor effect 308
depression co-morbid with 228
Down syndrome 283
frontotemporal dementia 348
treatment in depression 470
apex beat, in examination 119
aph-1 genes 289
aphasia 132
apnoea, sleep 703
apnoea-hypopnoea index (AHI) 703
apolipoprotein E (APOE) 244–245,
281–282
Alzheimer’s disease risk 240, 244–245,
271, 723
see also apolipoprotein E allele ε4
(APOE4)
binding to aggregated Aβ 245
gene function and expression 244–245
gene location and structure 244, 245
genetic testing and counselling 245–246
inheritance and clinical features 244
isofoms modulating lipid level for
neurons 245
late-life depression risk 461
polymorphisms 244, 245, 723
toxicity mechanism 244
apolipoprotein E allele ε2 (APOE2) 244
APOE 2/2 245
dementia incidence 217
dementia protective factor 210, 282
apolipoprotein E allele ε3 (APOE3) 244
APOE 3/3 245
APOE 3/4 245
dementia incidence 217
apolipoprotein E allele ε4 (APOE4) 29,
244, 245–246
AD risk 29, 127, 210, 271, 282, 293,
723
as antemortem marker 301
early life experience interactions 273
predictive testing for E4 allele 410
risk with one allele 246
South Asia 730
vascular risk factors modified by 272
APOE 4/4 245–246
delirium pathophysiology 197
dementia incidence 217
depression with 567
suicidal behaviour 561
Down syndrome and 282
apoklesis 36
apparent volume of distribution (V) 55–56
APP carboxyl terminus fragments (AICD)
239, 288
appearance
in Mental State Examination (MSE) 113
in physical examination 118
apetite dysregulation, Alzheimer’s disease
228–229, 826
apraxia
ideational, Alzheimer’s disease 227
ideomotor, Alzheimer’s disease 227
Area Agencies on Aging (AAA) 424
Area Health Authorities 746
arginine-vasopressin (AVP) 796
age-related changes 48
inappropriate secretion 538
receptors 48
artipiprazole
Alzheimer’s disease 314
bipolar disorder 582
dosage and adverse effects 313
effect on brain function 32
partial agonist at D2 receptors 57
in treatment-resistant depression 540
arrest, elderly offenders 696
arson 695
arterial spin label (ASL) imaging 435, 438
arteriosclerosis
historical aspects 4
silent cerebrovascular disease 344
artificial neural networks (ANNs) 39
Asia
depression incidence 486
depression prevalence 482–483,
483–485
see also East Asia; South Asia
Asians, in UK see South Asians (in UK)
Asp2 see BACE1
Asperger’s syndrome 696
assessment of mental health
ethnic groups 713
see also neuropsychological assessment
assisted living facilities, in US 790
Association for Frontotemporal Dementias (AFTD) 422, 424
asylums 745
atheroma, subclinical, vascular disease and
depression 470
atherosclerosis 272, 723
atropine, premedication before ECT 532
attention 195
alternating, testing 390
assessment 131, 138, 389–390, 391
confounding factors 390
deficits/impairment 137
in Lewy body dementias 364–365
delirium diagnosis 195
divided, testing 390
selective
Down syndrome 283
testing 389
simple span, testing 389
attributable fraction (AF) 847
audit, NHS continuing care 760
AUDIT (Alcohol Use Disorders Identification Test) 667
auditory hallucinations 114
incidence/prevalences 597
Lewy body dementias 365
auditory problems, management in AD 327
auscultation, in examination 119
Australia
depression prevalence 485
malnutrition prevalence 824
autoantibodies 124
autobiographical history 130
autoimmune diseases, investigations 124
Automated Geriatric Examination for
Computer Assisted Taxonomy
(AGECAT) see AGECAT
autonomic dysfunction
depression and vascular disease
469–470
Lewy body dementias 365
autonomy 766
autoradiography, hippocampus CA1
neuronal loss 260
Axis I and II disorders see under DSM-IV
axonal transport, impairment in AD 291
Ayurveda 405–406, 407
Ayurvedic medicines 405
Babinski sign, assessment 121
‘baby boomers’ 83, 770, 857
BACE1 254, 289–290
APP cleavage 289
expression 289
increased in AD 290
inhibition by native prion protein 377
knock-out mice 254, 290
regulators 290
synthesis and transport 290
BACE2 290
backward-digit span 131
Balanced Budget Act (BBA-97) (1997) 771
Balint’s syndrome 132
Baltimore Longitudinal Study of Ageing 65
barium X-ray tests 124
Barthel Index 180
basal ganglia, in OCD 633
BASDEC scale 142
BDNF see brain-derived neurotrophic factor (BDNF)
Beck Depression Inventory (BDI) 142, 569
Beck Depression Inventory II (BDI-II) 392
bedside assessment, of cognitive functioning
see cognitive functioning assessment
Beers criteria 795
Behavioral Rating Inventory of Executive Function - Adult version (BRIEF-A) 392
Behavioral Risk Factor Surveillance System (BRFSS) 673
behaviour
aggressive see aggressive behaviour
changes, cognitive assessment 129–130
context-dependent, personality disorders 657
impaired
Alzheimer’s disease 229, 312
dementia classification 202
see also behavioural disturbances
maladaptive interpersonal, in personality
disorders 659
in Mental State Examination (MSE) 113
positive reinforcing 543
rating/rating scales 141
rigidity 129
stabilization, delirium treatment 198
suicidal see suicidal behaviour
see also individual drug groups
behavioural model (in AD) 324
behavioural therapy
drug misuse 683
insomnia 701
multi-sensory 798
obsessive–compulsive disorder 633
see also cognitive behavioural therapy (CBT)
behavioural therapy
benefit 766
behavioural disturbances
Alzheimer's disease 228, 229, 295, 312
effect on caregivers 417, 830, 832
management see behavioural management, in AD
theories underlying 324
in care homes 78
dementia 210–211, 216
impact on caregivers 830
in offenders 696
in depression 498
FTD syndromes 348, 353
management see behavioural management
medical/neurological disorders 426–432
management see FTD syndromes 348, 353
in depression 498
in alcohol withdrawal 667
anxiolytic 625, 626
chronic/long-term use 680, 683
delirium controlled by in ECT 533
delirium induced/worsened by 198
dependence 626, 683
psychiatric history-taking 111–112
drug interactions 626, 627
efficacy in anxiety 626
increased sensitivity to 58
indications 680
South Asia 731
institutional use 680
long half-life 626
metabolism 626, 627
misuse 680–681
alcohol abuse with 681, 682
detection 682
gender and age 681
late-onset 681
treatment 683
OBRA Interpretive Guidelines 794
pharmacokinetics 625–626
prevalence of use 680
psychiatric morbidity with 681
sedative-hypnotics 625, 626
selection, criteria 627
short to intermediate half-life 626, 627
side effects 626–627, 642, 667
ultra-short half-life 626
withdrawal 626, 683
bereavement 459, 555–558
acute stress reaction due to 640
animal companion’s death 557
child/grandchild’s death 555
concerns after 555
early phases 556–557
later phases 557–558
pre-bereavement situation 555–556
PTSD after 641
spousal 498, 499, 555, 556
cause of depression 520
as status marker, and new roles 557
at time of death 556
see also grief
bereavement overload 557
‘best interests’ 853
best interest standard 411
beta-amyloid see amyloid beta (Aβ)
beta-blockers
anxiety/anxiety disorders 628–629
PTSD 642
β-sheets 287, 372
Bethlem Hospital 12
psychiatric geriatric unit 7, 12, 13
Beveridge Report 746
biochemistry, investigations 123–124, 345
biofeedback, memory training 406, 407
biological age, offenders, needs assessment 694
biological ageing 61
quantification 60
biological risk factors, as anxiety risk factor 620
biomarkers
of ageing, criteria for 65
Alzheimer’s disease 205, 299–303
treatment benefit identification 309
see also Alzheimer’s disease, antemortem markers
dementia diagnosis, impact on epidemiology studies 211
frontotemporal dementia 350–351
Lewy body dementias 366–367
biomedical theories, successful ageing 71, 72
bipolar disorder 500, 576–588
age of onset 573, 576–577
‘burn-out’ 576
classification 458
clinical features and health service usage 579
cognitive impairment 578–579
community vs hospital prevalence 576
course 577
definition/description 576
depression as first episode 573, 577
diagnosis, clinical implications 579
early-onset 576–577, 579
epidemiology 576
euthymic 579
functional impairment association 178
genetics/family history 577
history-taking and investigations 580
late-onset 460, 573, 576–577, 579
 genetics 461
magnetic resonance spectroscopy 449, 450
management 580–583
acute mania treatment 580–582
adherence/compliance 583
APA guidelines 582
challenges in and lack of trials 580
drug therapy 582
maintenance therapy 583
psychotherapy 583
manual-based medical care model 583
mortality 576
neuroimaging 578
outcome, relapse and hospitalization 577
psychiatric/medical co-morbidity 577–578, 583
rapid cycling, valproate therapy 581
refractory, management 540
stressful life events and 579
suicidal behaviour 560
switch from unipolar depression 577
treatment 539
vascular subtype 578, 579
see also depression (geriatric); mania
bipolar disorder medical care model (BCM) 383
bipolar II disorder 458, 497
Birren, James 60, 61
birth cohort differences, depression 618
bismuth encephalopathy 380
black Caribbean people (UK), depression 520, 521
attitudes to seeking help for 518, 522
barriers to care for 519–520
concepts and causation of 520
facilitators to care 519–520
Blessed Dementia Scale 170
Bleuler, Manfred 592
blood pressure
blood mononuclear cells (BMCs), genomics, 28
blood flow, changes, functional imaging 437–438
Bleuler, Manfred 592
blood pressure
blood pressure
high see hypertension
low, postoperative cognitive dysfunction 818, 820
low diastolic
AD risk relationship 272
depression relationship 468
white matter lesion risk 344
body mass index (BMI) 273, 825
sleep-disordered breathing 703
body image
body shape changes, sexuality and 707
body size, cellularity relationship, decreased life span 52
BOLD fMRI 28, 437–438
in examination 119
high see hypertension
low, postoperative cognitive dysfunction 818, 820
Borrelia burgdorferi (Lyme disease) 427–428
Boston Diagnostic Aphasia Exam 391
Boston Naming Test 391
bovine spongiform encephalopathy (BSE) 373, 375, 376
Braak staging 295
bradykinesia 133
brain atrophy 36
alcoholic dementia 378–379
bipolar disorder 578
brain-derived neurotrophic factor (BDNF) 42, 337
depression aetiology and 619
Brain Fitness programme 398
‘brain games’ 400
brain imaging
vascular dementia 345
white matter lesions 344, 490–491
see also neuroimaging

<table>
<thead>
<tr>
<th>SUBJECT INDEX</th>
</tr>
</thead>
<tbody>
<tr>
<td>brain injury, AD risk 272</td>
</tr>
<tr>
<td>brain mapping 29</td>
</tr>
<tr>
<td>3D, in depression 490</td>
</tr>
<tr>
<td>brain metabolites see myo-inositol</td>
</tr>
<tr>
<td>brain sclerosis see arteriosclerosis</td>
</tr>
<tr>
<td>brainstem respiratory neurons, degeneration 703</td>
</tr>
<tr>
<td>brain tumours, malignant, reversible dementia 386</td>
</tr>
<tr>
<td>brain volume changes with age, fMRI studies 435</td>
</tr>
<tr>
<td>reduced in Down syndrome 283</td>
</tr>
<tr>
<td>breathing disorders, sleep-related 703</td>
</tr>
<tr>
<td>brief alcohol counselling (BAC) 667</td>
</tr>
<tr>
<td>Brief Cognitive Rating Scale (BCRS) 166</td>
</tr>
<tr>
<td>Brief Psychiatric Rating Scale (BPRS) 312, 313</td>
</tr>
<tr>
<td>brief psychotherapy acute stress reaction 641</td>
</tr>
<tr>
<td>adjustment disorder 642</td>
</tr>
<tr>
<td>personality disorders 658</td>
</tr>
<tr>
<td>Bristol Activities of Daily Living Scale (BADL) 811</td>
</tr>
<tr>
<td>Broadmoor high security hospital 697</td>
</tr>
<tr>
<td>Buffon, M. Le Comte 3</td>
</tr>
<tr>
<td>burden of care, dementia see care, burden of buspirone 57, 627</td>
</tr>
<tr>
<td>efficacy and administration 627</td>
</tr>
<tr>
<td>in OCD 634</td>
</tr>
<tr>
<td>side effects 627</td>
</tr>
<tr>
<td>Butler Hospital (Rhode Island, USA) 799, 800</td>
</tr>
<tr>
<td>discharge diagnosis 800</td>
</tr>
<tr>
<td>partial hospital programme 800</td>
</tr>
<tr>
<td>butyrocholinesterase 305–306</td>
</tr>
<tr>
<td>reversible inhibitor 305</td>
</tr>
<tr>
<td>see also cholinesterase inhibitors; rivastigmine</td>
</tr>
<tr>
<td>CADASIL, genetic testingHuntington’s disease 127</td>
</tr>
<tr>
<td>Caeorhabditis elegans ageing, and genetics 52, 53</td>
</tr>
<tr>
<td>presenilins and y-secretase 289</td>
</tr>
<tr>
<td>caffeine, before ECT 532</td>
</tr>
<tr>
<td>CAGE screen 667, 673</td>
</tr>
<tr>
<td>calcipressin 282</td>
</tr>
<tr>
<td>calcium ions delirium pathophysiology 197</td>
</tr>
<tr>
<td>homeostasis defects in AD 292</td>
</tr>
<tr>
<td>calcium phosphate, accumulation 4</td>
</tr>
<tr>
<td>calculations, assessment 432</td>
</tr>
<tr>
<td>caloric intake restriction 53–54, 65</td>
</tr>
<tr>
<td>Cambridge ACE test 132</td>
</tr>
<tr>
<td>Cambridge Neuropsychological Tests Automated Battery (CANTAB) 392</td>
</tr>
<tr>
<td>CAMCOG, in CFAS I/II study 216</td>
</tr>
<tr>
<td>CAMDEX–DS 284</td>
</tr>
<tr>
<td>Canadian Academy of Geriatric Psychiatrists 861</td>
</tr>
<tr>
<td>Canadian Study of Health and Aging 675, 676</td>
</tr>
<tr>
<td>cancers, in learning disability 691</td>
</tr>
<tr>
<td>CANTAB 392</td>
</tr>
<tr>
<td>capacity see mental capacity</td>
</tr>
<tr>
<td>Capacity Act (2005) see Mental Capacity Act (2005)</td>
</tr>
<tr>
<td>Capgras syndrome 229, 312</td>
</tr>
<tr>
<td>carbamazepine acute mania 581</td>
</tr>
<tr>
<td>Alzheimer’s disease 320</td>
</tr>
<tr>
<td>monitoring 126</td>
</tr>
<tr>
<td>carbohydrate craving 348</td>
</tr>
<tr>
<td>cardiac side-effects, psychotropic drugs 125, 126</td>
</tr>
<tr>
<td>cardiac surgery, anaesthesia effect on cognitive decline 820, 821, 822</td>
</tr>
<tr>
<td>cardiovascular disease alcohol use and 675</td>
</tr>
<tr>
<td>dementia aetiology and 210, 723</td>
</tr>
<tr>
<td>depression association 509</td>
</tr>
<tr>
<td>see also heart disease</td>
</tr>
<tr>
<td>cardiovascular system dementia risk factor 210, 723</td>
</tr>
<tr>
<td>depression and mortality and 619</td>
</tr>
<tr>
<td>examination 118–119</td>
</tr>
<tr>
<td>care burden of dementia 66, 557, 731</td>
</tr>
<tr>
<td>palliative care and 839</td>
</tr>
<tr>
<td>see also caregivers/carers meanings of term 749, 767</td>
</tr>
<tr>
<td>see also caregivers/carers; community care; day care/services; long-term care</td>
</tr>
<tr>
<td>care arrangements, South Asia 731–732</td>
</tr>
<tr>
<td>caregivers/carers Alzheimer’s disease non-pharmacological interventions by 327</td>
</tr>
<tr>
<td>training, for behavioural interventions 325</td>
</tr>
<tr>
<td>communication with, long-term care in US 791, 792</td>
</tr>
<tr>
<td>condoning alcohol misuse 682</td>
</tr>
<tr>
<td>dementia patients care burden 66, 557, 731</td>
</tr>
<tr>
<td>day hospital benefits 754, 755</td>
</tr>
<tr>
<td>spirituality and 742</td>
</tr>
<tr>
<td>stress in 731</td>
</tr>
<tr>
<td>support for 9</td>
</tr>
<tr>
<td>dementia vs non-dementia 830</td>
</tr>
<tr>
<td>different cultures 714</td>
</tr>
<tr>
<td>elder abuse by 836</td>
</tr>
<tr>
<td>elderly, health status 556</td>
</tr>
<tr>
<td>to elderly people with learning disability 692</td>
</tr>
<tr>
<td>family see family caregivers impact of caring on 731, 756, 791</td>
</tr>
<tr>
<td>as imposters, delusions 326</td>
</tr>
<tr>
<td>needs, rehabilitation and 811</td>
</tr>
<tr>
<td>numbers, population demographics and 84</td>
</tr>
<tr>
<td>people acting as 829</td>
</tr>
<tr>
<td>pre-bereavement situation 556</td>
</tr>
<tr>
<td>public policy and cost implications 829</td>
</tr>
<tr>
<td>at risk of physical abuse 835</td>
</tr>
<tr>
<td>role in rehabilitation 811</td>
</tr>
<tr>
<td>selective prevention of mental disorders 845</td>
</tr>
<tr>
<td>spiritual support for patients 742, 743</td>
</tr>
<tr>
<td>stress 415–416, 417, 731</td>
</tr>
</tbody>
</table>
SUBJECT INDEX


cell-based therapies 334–335
resources 335


cellular ageing 55


center for Medicare and Medicaid Services (CMS) 794
regulations 794


central America, depression prevalence 483


central nervous system (CNS), endocrine system effects 45


cerebral blood flow reduced, delirium 196
regional, SPECT imaging and memory impairment 257–258


cerebral cortex asymmetry loss during ageing 37
atrophy alcoholic dementia 378–379
bipolar disorder 578
right-sided lesions, mania and 578
thinning, normal ageing 17


cerebral infarction, silent 344
bipolar disorder and 578

cerebral ischaemia, delirium pathophysiology 197

cerebral metabolism, indirect measurement using rCBF 258


cerebral reserve cognitive/neutral 272
limited, anaesthesia and dementia 817
reduced in old age 117


cerebrospinal fluid (CSF) analysis 127
Creutzfeldt–Jakob disease (CJD) 374
cryptococcosis 429
herpes simplex encephalitis 429–430
Lewy body dementias 366–367
Lyme disease 427
markers in AD 299
markers in FTD 350–351
monamine levels, in AD 300
tau protein 351
tuberculosis 426–427
vascular dementia diagnosis 345
cerebrovascular adverse events (CVAEs), antipsychotics in AD 318
cerebrovascular disease 342
bipolar disorder and mania co-morbid 578
definition 342
dementia association, definition 343
dementia risk factor 210, 342, 343
depression in Parkinson’s disease and 474
depression with see depression (geriatric); stroke
diagnosis 345
epidemiology 208, 343–344
gait 130
mania association 574, 578
mixed dementia 345
risk factors and vascular depression link 468


silent 344, 578
see also stroke; vascular disease


ces-d (Center for Epidemiological Studies Depression) Scale 416, 497
depression prevalence assessed by 479, 480, 481, 482


cfas studies see cognitive function and ageing studies (cfas)


chaperone proteins 272


cholera, j.m. 4
charged multivesicular body protein 2b (chmp2b) 353


charles bonnet syndrome 114, 597, 602
chemical shift correlated mrs, 2d (2d-cosy) 451


chemical shift correlated mrs, 3d (3d-cosy) 492


chest, examination 119


chest percussion 119


chest x-ray 124


childhood adversity depression aetiology 618
suicidal behaviour 560


china 737–740
dementia 737–738
access to treatment 738
prevalence/incidence 737–738
treatment 738
demographics 737
depression prevalence 482–483, 739
treatment 739
population pyramids and changing distribution 85, 737
suicide rates 739–740


chinese traditional medicine 738


chlorpromazine, in CJD 376


cholesterol
elevation, dementia risk factor 210, 272
reduced, depression association 469, 826


choline
deficit in AD 295, 299
increased with age 447
magnetic resonance spectroscopy 446, 447


cholinergic deficit Alzheimers disease 295, 299, 304, 703, 821–822


Lewy body dementias 364
cholinergic function, age-related decrease 58


cholinergic hypothesis, of AD 295, 296


cholinergic innervation/nurons loss in AD 299, 304
neocortex, loss in AD 295


cholinergic mechanism, anaesthesias causing delirium/dementia 821–822


cholinesterase inhibitors 299, 305


AD treatment 296–297, 345
assessment of effect by Global Deterioration Scale (GDS) 162
cardiac effects 125, 305
comparison of efficacy/tolerability 306
computer-assisted cognitive interventions with 399
delirium management 199


caregivers/carers continued
factors affecting 830
models 829–830
support for 829–834


caregiver self-assessment questionnaire 352


caregiving distress 829–830
care homes 78–82
aggression and sexually disinhibited behaviour 697
dementia patients 78–79, 760
emotional/social needs 80
evaluating experiences of 79–80
identity preservation 80
losses experienced by 80
quality of life and care 79
south Asia 731
supportive relationships 80
depression in 78, 813
management 526
prevention 845
disabilities/diseases requiring residence in 78
lack of activities in 79, 80
malnutrition 824
meal presentation and supervision 825
mental health problems 524
number of residents 78
person-centred care 79, 80
private sector 760
quality assessment, challenges of measuring 79
quality of care 79
quality of life in 79
enhancement, practical issues 80
social needs 761
successful, characteristics 81
see also institutional care; nursing homes
care in community 749–750, 756
psychotic disorders 606
care of the dying see dying, care of;
palliative care
care plans 761
assessment for 761
dementia 806
personaliﬁed care


case study example 762


care quality commission 747

care resources 90
limited in South Asia 731
careers see caregivers/carers
‘Care Trusts’ 747


cart analyses 847
casein kinase 2 (ck2) 292
‘caseness’ dementia 208, 223
depression 508
CASP-19 measure 186
casuistry 767
catatonic states 566
catechol-O-methyltransferase (COMT) inhibitors, depression in Parkinson’s disease 475
CATIE-AD trial (NIMH) 314, 318
C-BS measure 187
CBT see cognitive behavioural therapy (CBT)
<table>
<thead>
<tr>
<th>SUBJECT INDEX</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mental State Examination (MSE)</td>
</tr>
<tr>
<td>pre-existing, in Down syndrome, AD and</td>
</tr>
<tr>
<td>profiles in ageing conditions</td>
</tr>
<tr>
<td>cognitive behavioural therapy (CBT)</td>
</tr>
<tr>
<td>case example</td>
</tr>
<tr>
<td>‘Coping with Depression’ (CWD) course</td>
</tr>
<tr>
<td>depression management</td>
</tr>
<tr>
<td>in Parkinson’s disease</td>
</tr>
<tr>
<td>dysthymia</td>
</tr>
<tr>
<td>efficacy</td>
</tr>
<tr>
<td>indicated prevention of depression</td>
</tr>
<tr>
<td>insomnia management</td>
</tr>
<tr>
<td>internet-based</td>
</tr>
<tr>
<td>‘medically unexplained symptoms’</td>
</tr>
<tr>
<td>in OCD</td>
</tr>
<tr>
<td>psychotic disorder management</td>
</tr>
<tr>
<td>outcome</td>
</tr>
<tr>
<td>in somatoform disorders</td>
</tr>
<tr>
<td>cognitive decline</td>
</tr>
<tr>
<td>definition</td>
</tr>
<tr>
<td>Down syndrome</td>
</tr>
<tr>
<td>normal ageing</td>
</tr>
<tr>
<td>profiles in ageing conditions</td>
</tr>
<tr>
<td>progressive, in AD</td>
</tr>
<tr>
<td>white matter lesions (WMLs)</td>
</tr>
<tr>
<td>see also cognitive impairment</td>
</tr>
<tr>
<td>cognitive deficits see cognitive impairment</td>
</tr>
<tr>
<td>cognitive disorders classification</td>
</tr>
<tr>
<td>with many causes, dementia as</td>
</tr>
<tr>
<td>cognitive distortions</td>
</tr>
<tr>
<td>in personality disorders</td>
</tr>
<tr>
<td>cognitive domains, evaluation</td>
</tr>
<tr>
<td>see also neuropsychological assessment</td>
</tr>
<tr>
<td>cognitive dysfunction, postoperative see postoperative cognitive dysfunction (POCD)</td>
</tr>
<tr>
<td>cognitive enhancement</td>
</tr>
<tr>
<td>cognitive training see cognitive training drugs see cholinesterase inhibitors</td>
</tr>
<tr>
<td>memory training see memory training neurofeedback</td>
</tr>
<tr>
<td>types</td>
</tr>
<tr>
<td>cognitive enhancers see cholinesterase inhibitors; memantine</td>
</tr>
<tr>
<td>Cognitive Function and Ageing Studies (CFAS)</td>
</tr>
<tr>
<td>aims</td>
</tr>
<tr>
<td>CFAS I as resource</td>
</tr>
<tr>
<td>screening interview</td>
</tr>
<tr>
<td>study population</td>
</tr>
<tr>
<td>CFAS II as resource</td>
</tr>
<tr>
<td>screening interview</td>
</tr>
<tr>
<td>study population</td>
</tr>
<tr>
<td>dementia risk factors</td>
</tr>
<tr>
<td>funding from MRC</td>
</tr>
<tr>
<td>methodology</td>
</tr>
<tr>
<td>content</td>
</tr>
<tr>
<td>interview method</td>
</tr>
<tr>
<td>depression with cognitive deficits</td>
</tr>
<tr>
<td>dosing</td>
</tr>
<tr>
<td>duration of use</td>
</tr>
<tr>
<td>fMRI studies of efficacy</td>
</tr>
<tr>
<td>initiation</td>
</tr>
<tr>
<td>Lewy body dementias</td>
</tr>
<tr>
<td>visual hallucination management</td>
</tr>
<tr>
<td>neuropsychiatric effects</td>
</tr>
<tr>
<td>non-responders</td>
</tr>
<tr>
<td>as part of rehabilitation</td>
</tr>
<tr>
<td>prescribing and monitoring</td>
</tr>
<tr>
<td>rationale for</td>
</tr>
<tr>
<td>selection/choice</td>
</tr>
<tr>
<td>side effects</td>
</tr>
<tr>
<td>switching</td>
</tr>
<tr>
<td>vascular dementia</td>
</tr>
<tr>
<td>see also acetylcholinesterase inhibitors; donepezil; galantamine; rivastigmine cholinomimetics, in AD</td>
</tr>
<tr>
<td>chorea</td>
</tr>
<tr>
<td>Christians, numbers of adherents</td>
</tr>
<tr>
<td>Chronic Care Model (CCM)</td>
</tr>
<tr>
<td>chronic fatigue syndrome</td>
</tr>
<tr>
<td>chronic illness increase in and concerns over</td>
</tr>
<tr>
<td>prevention of mental disorders in</td>
</tr>
<tr>
<td>spirituality and</td>
</tr>
<tr>
<td>see also physical illnesses</td>
</tr>
<tr>
<td>chronic obstructive pulmonary disease (COPD)</td>
</tr>
<tr>
<td>chronic wasting disease (CWD)</td>
</tr>
<tr>
<td>chronological ageing</td>
</tr>
<tr>
<td>cingulate cortex see anterior cingulate cortex; posterior cingulate cortex circadian rhythms in AD</td>
</tr>
<tr>
<td>age-related changes</td>
</tr>
<tr>
<td>pineal gland control of</td>
</tr>
<tr>
<td>restless legs syndrome and</td>
</tr>
<tr>
<td>of secretion</td>
</tr>
<tr>
<td>cortisol</td>
</tr>
<tr>
<td>prolactin</td>
</tr>
<tr>
<td>treatment of disturbances</td>
</tr>
<tr>
<td>circulocution, Alzheimer’s disease</td>
</tr>
<tr>
<td>cirrhosis</td>
</tr>
<tr>
<td>citalopram Alzheimer’s disease</td>
</tr>
<tr>
<td>anxiety/anxiety disorders</td>
</tr>
<tr>
<td>depression</td>
</tr>
<tr>
<td>depression in Parkinson’s disease</td>
</tr>
<tr>
<td>classification see entries beginning DSM or ICD; specific disorders</td>
</tr>
<tr>
<td>Clinical Dementia Rating (CDR)</td>
</tr>
<tr>
<td>AD8 scores</td>
</tr>
<tr>
<td>adaptations</td>
</tr>
<tr>
<td>CDR-SB</td>
</tr>
<tr>
<td>characteristics</td>
</tr>
<tr>
<td>cholinergic deficit in moderate/severe AD</td>
</tr>
<tr>
<td>chronic care facilities (CDR-CC)</td>
</tr>
<tr>
<td>development</td>
</tr>
<tr>
<td>driving in dementia, decision</td>
</tr>
<tr>
<td>early stages of dementia</td>
</tr>
<tr>
<td>GDS comparison</td>
</tr>
<tr>
<td>global scale</td>
</tr>
<tr>
<td>interview</td>
</tr>
<tr>
<td>multi-axial staging</td>
</tr>
<tr>
<td>overview</td>
</tr>
<tr>
<td>potential limitations</td>
</tr>
<tr>
<td>scale and details</td>
</tr>
<tr>
<td>scoring</td>
</tr>
<tr>
<td>semi-structured interview with informant</td>
</tr>
<tr>
<td>stability over time</td>
</tr>
<tr>
<td>time course of changes (normal to AD)</td>
</tr>
<tr>
<td>validity and reliability</td>
</tr>
<tr>
<td>clinical governance</td>
</tr>
<tr>
<td>Clinical Institute Withdrawal Assessment Scale for Alcohol (CIWA-Ar)</td>
</tr>
<tr>
<td>clinical neuropsychological assessment</td>
</tr>
<tr>
<td>see also under neuropsychological assessment</td>
</tr>
<tr>
<td>clinical neuropsychology role</td>
</tr>
<tr>
<td>clinical trials, regenerative medicine, design</td>
</tr>
<tr>
<td>clinicians see general practitioners (GPs); psychotherapists</td>
</tr>
<tr>
<td>Clock Drawing Test</td>
</tr>
<tr>
<td>clomipramine, OCD treatment</td>
</tr>
<tr>
<td>clonazepam</td>
</tr>
<tr>
<td>REM sleep behaviour disorder</td>
</tr>
<tr>
<td>clozapine acute mania</td>
</tr>
<tr>
<td>cardiac effects</td>
</tr>
<tr>
<td>Lewy body dementias</td>
</tr>
<tr>
<td>monitoring</td>
</tr>
<tr>
<td>psychotic disorders</td>
</tr>
<tr>
<td>Cockayne syndrome type 1 (CS)</td>
</tr>
<tr>
<td>Cockroft–Gault (CG) equation</td>
</tr>
<tr>
<td>cognition/cognitive abilities age-related changes</td>
</tr>
<tr>
<td>brain locations and specific abilities</td>
</tr>
<tr>
<td>fluid vs crystallized abilities</td>
</tr>
<tr>
<td>‘general slowing theory’</td>
</tr>
<tr>
<td>normal vs abnormal</td>
</tr>
<tr>
<td>quantitation</td>
</tr>
<tr>
<td>response times association</td>
</tr>
<tr>
<td>sensory changes affecting</td>
</tr>
<tr>
<td>study methodologies</td>
</tr>
<tr>
<td>terminal decline</td>
</tr>
<tr>
<td>testing for see neuropsychological assessment alcohol use and</td>
</tr>
<tr>
<td>assessment see cognitive functioning assessment</td>
</tr>
<tr>
<td>assessment scales</td>
</tr>
<tr>
<td>in behavioural variant FTD</td>
</tr>
<tr>
<td>Down syndrome and</td>
</tr>
<tr>
<td>dysfunctional see cognitive decline; cognitive impairment fluctuations, in Lewy body dementias</td>
</tr>
<tr>
<td>lifelong optimal level, prediction</td>
</tr>
<tr>
<td>of secretion quantitation</td>
</tr>
<tr>
<td>restless legs syndrome and</td>
</tr>
<tr>
<td>age-related changes</td>
</tr>
<tr>
<td>brain locations and specific abilities</td>
</tr>
<tr>
<td>cortisol</td>
</tr>
<tr>
<td>prolactin</td>
</tr>
<tr>
<td>treatment of disturbances</td>
</tr>
<tr>
<td>circumlocution, Alzheimer’s disease</td>
</tr>
<tr>
<td>cirrhosis</td>
</tr>
<tr>
<td>citalopram Alzheimer’s disease</td>
</tr>
<tr>
<td>anxiety/anxiety disorders</td>
</tr>
<tr>
<td>depression</td>
</tr>
<tr>
<td>depression in Parkinson’s disease</td>
</tr>
<tr>
<td>classification see entries beginning DSM or ICD; specific disorders</td>
</tr>
<tr>
<td>Clinical Dementia Rating (CDR)</td>
</tr>
<tr>
<td>AD8 scores</td>
</tr>
<tr>
<td>adaptations</td>
</tr>
<tr>
<td>CDR-SB</td>
</tr>
<tr>
<td>characteristics</td>
</tr>
<tr>
<td>cholinergic deficit in moderate/severe AD</td>
</tr>
<tr>
<td>chronic care facilities (CDR-CC)</td>
</tr>
<tr>
<td>development</td>
</tr>
<tr>
<td>driving in dementia, decision</td>
</tr>
<tr>
<td>Cognitive Function and Ageing Studies (CFAS) continued</td>
</tr>
<tr>
<td>--------------------------------------------------------</td>
</tr>
<tr>
<td>study population 215–216</td>
</tr>
<tr>
<td>neuropathological factors in dementia 218</td>
</tr>
<tr>
<td>prevalence/incidence of dementia 216, 217</td>
</tr>
<tr>
<td>selected findings 216</td>
</tr>
<tr>
<td>study design 213, 215</td>
</tr>
<tr>
<td>cognitive functioning assessment 137, 390, 391</td>
</tr>
<tr>
<td>cognitive gerontology 60–64</td>
</tr>
<tr>
<td>depression relationship, in Parkinson’s</td>
</tr>
<tr>
<td>decision-making capacity impairment</td>
</tr>
<tr>
<td>day hospitals role 754</td>
</tr>
<tr>
<td>bipolar disorder 578–579</td>
</tr>
<tr>
<td>Alzheimer’s disease 226–227</td>
</tr>
<tr>
<td>alcoholic dementia 378, 379</td>
</tr>
<tr>
<td>in Africa 735</td>
</tr>
<tr>
<td>study design 213, 215</td>
</tr>
<tr>
<td>cognitive functioning assessment 137, 390, 391</td>
</tr>
<tr>
<td>Alzheimer’s disease 233</td>
</tr>
<tr>
<td>in Down syndrome 283–284</td>
</tr>
<tr>
<td>at bedside 128–134</td>
</tr>
<tr>
<td>cognitive domain assessment 131–133, 137</td>
</tr>
<tr>
<td>cognitive rating scales 130–131</td>
</tr>
<tr>
<td>history-taking 129–130</td>
</tr>
<tr>
<td>functional ability prediction and 137</td>
</tr>
<tr>
<td>ethnic groups/cultural differences 715</td>
</tr>
<tr>
<td>in general hospitals 804</td>
</tr>
<tr>
<td>see also Mental State Examination (MSE)</td>
</tr>
<tr>
<td>cognitive gerontology 60–64</td>
</tr>
<tr>
<td>aims 60</td>
</tr>
<tr>
<td>see also cognition/cognitive abilities, age-related changes</td>
</tr>
<tr>
<td>cognitive impairment</td>
</tr>
<tr>
<td>in Africa 735</td>
</tr>
<tr>
<td>alcohol abuse causing 665, 676</td>
</tr>
<tr>
<td>alcoholic dementia 378, 379</td>
</tr>
<tr>
<td>Alzheimer’s disease 226–227</td>
</tr>
<tr>
<td>bipolar disorder 578–579</td>
</tr>
<tr>
<td>consent for sexual relations and 75</td>
</tr>
<tr>
<td>day hospitals role 754</td>
</tr>
<tr>
<td>decision-making capacity impairment 177</td>
</tr>
<tr>
<td>depression relationship, in Parkinson’s disease 474</td>
</tr>
<tr>
<td>depression with 386, 458, 495, 499, 505, 568–569</td>
</tr>
<tr>
<td>depression treatment effect 394</td>
</tr>
<tr>
<td>recovery 234–235, 394</td>
</tr>
<tr>
<td>treatment of 499</td>
</tr>
<tr>
<td>ECT side effect 530</td>
</tr>
<tr>
<td>effect on functional abilities 177–178</td>
</tr>
<tr>
<td>in FTD 353</td>
</tr>
<tr>
<td>functional disability associated 66, 67</td>
</tr>
<tr>
<td>Geriatric Depression Scale use in 154</td>
</tr>
<tr>
<td>global, dementia as 201, 208</td>
</tr>
<tr>
<td>late-onset schizophrenia 598</td>
</tr>
<tr>
<td>Lewy body dementia 364–365</td>
</tr>
<tr>
<td>management 367–368</td>
</tr>
<tr>
<td>in mania 578–579</td>
</tr>
<tr>
<td>normal ageing changes vs 137, 209, 392–394</td>
</tr>
<tr>
<td>personality disorders vs diseases with 657</td>
</tr>
<tr>
<td>postoperative see postoperative cognitive dysfunction (POCD)</td>
</tr>
<tr>
<td>progressive, in AD 226</td>
</tr>
<tr>
<td>psychotic disorders 593, 606</td>
</tr>
<tr>
<td>recovery, in depression 234–235, 394</td>
</tr>
<tr>
<td>schizophrenia 593</td>
</tr>
<tr>
<td>screening, in general hospitals 804</td>
</tr>
<tr>
<td>vascular 342, 343</td>
</tr>
<tr>
<td>see also cognitive decline</td>
</tr>
<tr>
<td>cognitive impairment with no dementia (CIND) 201, 209</td>
</tr>
<tr>
<td>in Africa 275</td>
</tr>
<tr>
<td>cognitive interventions</td>
</tr>
<tr>
<td>AD management 326</td>
</tr>
<tr>
<td>AD prevention 275</td>
</tr>
<tr>
<td>see also cognitive training</td>
</tr>
<tr>
<td>cognitive model, of depression 543</td>
</tr>
<tr>
<td>cognitive prosthesis intervention 326</td>
</tr>
<tr>
<td>cognitive rating scales 130–131</td>
</tr>
<tr>
<td>cognitive rehabilitation, definition 397</td>
</tr>
<tr>
<td>cognitive reserves, AD risk 272</td>
</tr>
<tr>
<td>cognitive stimulation 813</td>
</tr>
<tr>
<td>definition 397</td>
</tr>
<tr>
<td>cognitive training 397–398</td>
</tr>
<tr>
<td>comprehensive programme 399</td>
</tr>
<tr>
<td>computer-assisted interventions 398–399</td>
</tr>
<tr>
<td>effect on brain function 400</td>
</tr>
<tr>
<td>future directions 399–400</td>
</tr>
<tr>
<td>long-term outcomes 399</td>
</tr>
<tr>
<td>non-compliance 400</td>
</tr>
<tr>
<td>see also memory training</td>
</tr>
<tr>
<td>Cohen–Mansfield Agitation Inventory (CMAI) 312, 313</td>
</tr>
<tr>
<td>Collaborative Depression Study 503</td>
</tr>
<tr>
<td>collateral sprouting 42, 43</td>
</tr>
<tr>
<td>commissioner–provider split 747</td>
</tr>
<tr>
<td>Commission for Social Care Inspection (CSCI) 79</td>
</tr>
<tr>
<td>communication</td>
</tr>
<tr>
<td>in care homes 79, 80</td>
</tr>
<tr>
<td>difficulties in history-taking 601</td>
</tr>
<tr>
<td>ethnic groups 714</td>
</tr>
<tr>
<td>family/caregivers with psychiatrist in long-term care 791, 792</td>
</tr>
<tr>
<td>non-verbal, different cultures 714</td>
</tr>
<tr>
<td>in US private practice 778</td>
</tr>
<tr>
<td>community-based ambulatory care, in US 777–784</td>
</tr>
<tr>
<td>see also private practice (US)</td>
</tr>
<tr>
<td>community care 746, 750, 753</td>
</tr>
<tr>
<td>elderly people with learning disability 691–692</td>
</tr>
<tr>
<td>post-discharge, suicidal behaviour 563</td>
</tr>
<tr>
<td>in US 783</td>
</tr>
<tr>
<td>Community Care Act 2005 853</td>
</tr>
<tr>
<td>Mental Health Act 1983 851</td>
</tr>
<tr>
<td>Mental Health Act 2007 852</td>
</tr>
<tr>
<td>Percy Commission 850</td>
</tr>
<tr>
<td>computational anatomy, in AD 262–270</td>
</tr>
<tr>
<td>cortical maps in MCI vs AD 264</td>
</tr>
<tr>
<td>cortical thickness mapping 262–264</td>
</tr>
<tr>
<td>definition/description 262</td>
</tr>
<tr>
<td>hippocampal radial mapping 268, 269</td>
</tr>
<tr>
<td>tensor-based morphometry 265–268</td>
</tr>
<tr>
<td>time-lapse maps and trajectory 264–265</td>
</tr>
<tr>
<td>computed tomography (CT) 124, 125, 433</td>
</tr>
<tr>
<td>Alzheimer’s disease 301</td>
</tr>
<tr>
<td>herpes simplex encephalitis 431</td>
</tr>
<tr>
<td>principle and technique 433</td>
</tr>
<tr>
<td>resolution improvements 433</td>
</tr>
<tr>
<td>structural imaging of brain 433</td>
</tr>
<tr>
<td>white matter lesions 344</td>
</tr>
<tr>
<td>computer-assisted cognitive interventions 398–399</td>
</tr>
<tr>
<td>medication with 399</td>
</tr>
<tr>
<td>COMT inhibitors, depression in Parkinson’s disease 475</td>
</tr>
<tr>
<td>confidentiality</td>
</tr>
<tr>
<td>different cultures 714</td>
</tr>
<tr>
<td>family involvement (US private practice) 781</td>
</tr>
<tr>
<td>genetic tests 127</td>
</tr>
<tr>
<td>confusion</td>
</tr>
<tr>
<td>acute see delirium</td>
</tr>
<tr>
<td>chronic see dementia</td>
</tr>
<tr>
<td>ECT side effect 529, 532, 533</td>
</tr>
</tbody>
</table>
Darby and Joan syndrome 695
dehydropiandrosterone sulfate (DHEAS) 47
dehydropiandrosterone (DHEA) 47
dehydratation 118
degree of pineal calcification (DOC) 300
dehydration 118
dehydriopiodristone (DHEA) 47
replacement therapy 47
dehydropiandrosterone sulfate (DHEAS) 47
delirium 195–200, 805
active 195
aetiology 196–197
Alzheimer’s disease with 226, 326–327
anaesthesics effect 817–818
cholinergic mechanisms 821–822
costs related to 195, 805
dementia confusion 197–198, 204
dementia with 198, 226, 326–327, 805
diagnosis, missed in general care hospitals 803, 805
diagnosis in offenders 696
differential diagnosis, schizophrenia 599–600
drugs causing 198
DMT-IV diagnostic criteria 195, 196, 204
emergence (after anaesthesia) 817
focused intervention trials, impact 197
history-taking 601
ICD-10 classification 106
incident (after admission to hospital) 805
interval (after anaesthesia) 817–818
investigations 123
liaison psychiatry and 805
malnutrition as risk factor 824
management 197
medical diagnosis with 805
misdiagnosis 195, 196, 803
mixed 195
MMSE in assessment 146
mortality 838
paranoid 600
pathophysiology 196–197
population at risk 196
post-hip fracture 197
risk/prevention 199, 805, 807
postoperative 817–818
prediction, IQCODE use 149
prescribing/preparing factors 818
risk factors 818
presentation and symptoms 195–196
prevalence 195, 805
prevalent (at admission to hospital) 805
prevention 197
quiet 195, 196
rating scales 195
as risk factor for death/dementia 195, 204
risk factors 196, 198, 805, 818, 824
subcategories 195
subsyndromal 196
susceptibility, factors 196, 198
treatment approaches 198–199, 805, 838
behavioural stabilization 198
drug treatment 198–199
treatment of causes 198
‘delirium with Lewy bodies’ 366
Delis-Kaplan battery 391
delusion(s) 114
aetiology 605
Alzheimer’s disease 228, 229, 312, 324
of abandonment 326
as confabulation 326
drug management see antipsychotic drugs
non-pharmacological management 326–327
of theft 114, 229, 312, 326, 600
CBT outcome 606
classification 114
in depression, management 553
incidence/prevalences 597
paranoid 599
Alzheimer’s disease 229, 312
partition 596, 599, 605
persecutory 592, 599, 605
primary 114
schizophrenia 599
types 605
delusional disorder
differential diagnosis 600–601
late-onset 592, 593, 601
late-onset schizophrenia vs 593, 596, 601
organic, schizophrenia vs 600
schizophrenia vs 596
dementia
in 19th century 4
aetiology 723–724
cardiovascular risk factors 723
cross-cultural 719
environmental factors 723, 805, 810
factors 723
nutritional factors 723
aggressive behaviour 229, 695
alcoholic see alcoholic dementia
in Alzheimer’s disease
subtypes (ICD-10 DCR) 106
see also Alzheimer’s disease (AD)
Alzheimer’s disease without 205
anaesthesia effect 817
cholinergic mechanisms 821–822
assessment, NICE guidance 806
behavioural and psychological symptoms (BPSD) 210–211, 312, 719
in Africa 734
assessment 762
management and prevention 762–763
care in
China and Hong Kong 738
ethics see ethics/ethical issues
goals 410, 413
South Asia 731–732
care burden 66, 557, 731
caregivers see caregivers/carers
care homes see care homes
care vs treatment needs 750, 751
causes of death 838
in China 737–738
classification 105–108, 201–206, 342
10/66 group criteria 204–205
‘Alzheimerization’ 204
current systems 201
DSM-IV 107
DSM-IV-TR 201, 202, 208
future challenges 204–205
future groupings 107
historical background 203–204
The text is too long to display here. It appears to be an index of subjects related to dementia, Alzheimer's disease, and other related topics.
depression (geriatric) continued
protective factors
in China 739
strengthening in preventive
programmes 846
psychomotor changes 113
psychosocial factors affecting 515
psychotic 496, 566
ECT for 530, 532
offenders 696, 697
public health education on 526
rapid cycling 458, 474
rating scales 141, 497–498, 569
used in Parkinson’s disease 473
see also Geriatric Depression Scale
(GDS)
reasons for not seeking help 518
recurrent 98, 458, 496
amygdala volume reduction 489
relapse rates, after ECT 530
response inhibition, neuroimaging 489,
491
reversible dementia 386
risk factors 486–487, 506
reducing in preventive programmes
846
screening 511, 515
different ethnic groups 714
in general hospitals 804
by GPs 525
South Asia 731
seasonal pattern 566
secondary 510
severe 617
ECT for 529
with psychotic features, case study
636–637
sociodemographic correlates
(cross-cultural) 718–719
somatization 495, 508, 521, 524
somatized, features 510, 638
as spectrum 566
spirituality and 742
stigma surrounding 519, 521, 524, 526
stress triggering 509
as stroke risk factor 469, 567
subsyndromal 498, 566
suicidal ideation 497, 512, 560, 806
management 563
suicide 505, 512, 524
assessment 553
general hospital patients 806
management 553, 563
as outcome 505, 509, 512, 524
prevention 562
risk, hospitalization in 553, 562
risk/risk factors 500, 553
support network, negative exchange loop
464–465
as syndrome 565–568
assessment 568–570
management 511, 563
barriers to (ethnic groups) 518–519
China 739
community settings 524–528
 costs 565

SUBJECT INDEX

culturally sensitive 526
discontinuities in system for 518
drug therapy after ECT 530
ECT see electroconvulsive therapy
(ECT)
in general hospitals 806
inadequacy 511
in medical psychiatric inpatient unit
788
personality disorder impact 652
pharmacological 537–542
post-stroke 516
pretreatment considerations 537
repetitive transcranial magnetic
stimulation (rTMS) 534
in residential homes 526
response, MRI volumetric studies
489–490
see also antidepressants; depression
(geriatric), management
treatment-resistant antidepressant
management 539–540
ECT for 530
unipolar 496
unipolar to bipolar switch 577
‘vascular’ see vascular depression
vascular disease and 468–472, 487
depression as risk factor for 469, 497
depression complicating 468, 496–497
relationship mechanisms 469–470
suicide prevention/risk 560, 561
treatment 470
vulnerability 496
white matter hyperintensities (WMHs)
490, 496
without sadness 114, 496
depression–executive dysfunction syndrome
458, 468, 474
‘depression of Alzheimer’s disease’ (dAD)
228
see also under depression (geriatric)
depressive episode
classification 457–458
major see depression, major
minor 457
depressive pseudodementia 386, 474
depressive syndromes 565–572
deprivation of liberty 10, 761, 853
Deprivation of Liberty Safeguards (DOLS)
761, 851, 853
desflurane 822
desipramine 537
in anxiety/anxiety disorders 628
developmental disability, in offenders 696
dexamethasone suppression test (DST) 569
dexametomidine, delirium management
199
DHA-derived neuroprotectin D1 (NPD1)
404
dhat 714
diabetes mellitus
beta-amyloid clearance reduction
272–273
depression as risk factor 469
depression complicating 468
insulin-dependent, ECT contraindication
and 531
myo-inositols changes 448–449
Diagnostic and Statistical Manual of Mental
Disorders IV see DSM-IV
dialectical behaviour therapy (DBT) 546
personality disorders 658
studies/trials using 546
diazepam
half-life 680
metabolism 56
pharmacodynamics 58
diet
AD prevention 275
memory improvement 403–404
see also nutrition; nutritional deficiencies
dietary restriction, longevity and 53
differential reinforcement 325
diffuse plaques 287
diffusion tensor imaging (DTI)
alcoholic dementia 379
effects of ageing 18
limitations 21
normal ageing 17, 18
quantification of data 18
regional quantification of data 18
white-matter lesions in depression
490–491
diltiazem, pharmacodynamics 58
diphenhydramine, pharmacodynamics 58
directly managed units (DMUs) 746
Direct Observation of non-Clinical Skills
(DoNCS) 862
disability 66
assessment of extent 811
care home residents 78
cognitive impairment contributing to 67
definition 66
depression aetiology 719
levels, age-specific trends 87–88
physical/mental disorder contribution
722–723
prevalence 207
affluent vs non-affluent countries 207
decline from 1980s 67
estimating methods 67
increase in and concerns over 183
in terms of activities of daily living
66–67
progressive nature 763
risk with alcohol use 676
weighting, of dementia 722
disability adjusted life years (DALYs) 176
Disability Assessment for Dementia (DAD)
305
disability-free life expectancy 67
‘disability paradox’ 184, 186
disclosure avoidance (by patients),
personality disorders 655–656
discrimination
age-based (Equality Bill 2009) 525
elderly people with learning disability
692
against lesbian, gay and bisexual (LGB)
people 76
disengagement theory 731
DSM-IV continued
personality disorder vs unremitted disorder 657
symptomatology 649
see also anxiety disorders; depression (geriatric)
Axis II disorders 649, 651
see also personality disorders
bipolar disorder 458, 576
dementia, prevalence in low-middle-income countries 720
depression 457–458, 495, 508, 565, 566
in Parkinson’s disease 473
prevalence in America 480, 482
prevalence in Asia 483
prevalence in Australia 485
prevalence in Europe 480
dysphasia, Alzheimer’s disease 226
dysfunctional beliefs 639
dysfunctional behaviour 639
DIC-10 differences 107
limitations 107
mania 576
mood disorders 457–459
neurotic disorders 611–612, 614
personality disorders 656
post-traumatic stress disorder 641
somatoform disorders 636
vascular dementia 342
DSM-IV-TR
delirium 204
diagnostic criteria 195, 196
dementia 201, 202, 208
personality disorders 649, 651, 655, 657
DSM-V
personality disorders 652
psychotic disorders 591, 592
DTI see diffusion tensor imaging (DTI)
duty of care 766
dying, care of 838–843
international perspective 838–839
see also palliative care
dynamic psychotherapy, PTSD 642
DYRK1A gene 282
Dysarthria 330, 334
Dysfunctional behaviour 639
Dysfunctional beliefs 639
Dyslexia 132
Dyspareunia 707, 708–709
Dysphasia, Alzheimer’s disease 226
Dysphonia 113
dysprosodia 132
dysplasia 227, 348
development 282
economics of ageing 90–96
see also costs(s); health economics
economic stress, carers of dementia 731
ectodomain shedding 289
education coping behaviour link 465
as dementia risk factor 209
depression prevalence correlation 719
effect on normal vs abnormal cognitive ageing 209
geriatric psychiatry see training health link 464
healthy/affordable eating 826
liaison psychiatry 804–805
long-term care staff 791
MMSE and 145
nutrition 826, 827
by private practitioners 780
professional liaison psychiatry 804–805
medical psychiatric inpatient unit 789
suicide prevention strategy 561, 562
see also training
EEG see electroencephalography (EEG)
eicosapentaenoic acid (EPA) 275, 404
eigenvalues 18
ejaculation 706
disorders 708
premature 708
problems 707
elder abuse 835–837
abuser characteristics 836
categories 835
definition 835
domestic 835
institutional 835, 836
management 836
natural history 836
physical 835, 836
prevalence and incidence 835
psychological 835, 836
recognition 836
risk factors 835, 836
signs and symptoms 837
victim characteristics 835–836
Elder Life Program, The 805
‘elderly adolescentism’ 559
elderly people see older people; specific topics
elderly support ratio 207
electrocardiography (ECG) 125–126, 345
electroconvulsive therapy (ECT) 529–536
administration 532
adverse effects 530, 531, 533
bilateral vs unilateral electrode placement 532
bipolar disorder 582
brief pulse 532, 533
consent 529, 533
contraindications 531–532
depression 511, 529–530, 532, 563
continuation pharmacotherapy after 530
evidence base for efficacy 529–530
meta-analysis 530
in Parkinson’s disease 475, 531
dose titration 532
effect in dementia 533
frequency of use in elderly 529
indications 529–531
involuntary 533
maintenance and continuation 532–533
mania 531
modified, in China 739
NICE guidance 530, 531, 533
obsessive–compulsive disorder 634
outpatient 532
psychiatric history-taking 110
schizophrenia 531
seizures during 532
electroencephalography (EEG) 126
Creutzfeld–Jakob disease (CJD) 126, 374
Lewy body dementia 366
neurofeedback for cognitive enhancement 406
quantitative (qEEG) 126
rhythms normal aging (resting EEG) 38
quantitative 39
surface Laplacian transformation (coherence analysis) 38
sleep, in depression 569
electrolytes, alcohol abuse effect on 666
electromyogram (EMG) 702
Ely Hospital Report (1969) 9
Embryonic stem cells (ESCs) 330, 334, 335
Emergency Medical Service (EMS) 745–746
emotional blunting
frontotemporal dementia 348
PTSD 641
emotional distress
distinction with mental illness 97
presentations in different cultural groups 714
see also distress; stress
emotional liability 114
empowering elderly people 848
enalapril, pharmacodynamics 58
encephalitis, herpes simplex see herpes simplex encephalitis
encephalopathy, bismuth 380
endocrine system, effects on CNS 45
end-of-life care
indications 839–840
legal frameworks, NHS continuing care 761
NHS continuing care 764–765
people with learning disability 692
see also palliative care
endoscopy 124
endothelial dysfunction, vascular disease
and depression 470
enhanced outpatient treatment programme 801
Enriched Opportunities Programme 81
enteral nutritional support, decision on, ethics 413
entorhinal cortex, neurofibrillary tangles 295
eyes continued
  inspection 118
  movements, assessment 133
face–name associations 398
functional MRI (fMRI) 439
face recognition impairment, semantic dementia 349
Facial Recognition Task 392
faith communities, supportive 743
falls
Alzheimer’s disease 230, 763
Lewy body dementias 366
minimizing 763
risk assessment 763
families
care role, US private practice and 781
communication with, long-term care in US 791, 792
contact with, in schizophrenia 604
dementia care by, in China 738
different cultures 714
disability affecting, rehabilitation and 811
dysfunctional relationships, alcohol abuse and 666
end-of-life issues, NHS continuing care 764
extended, depression management 526
informal carers 91
multigenerational transactions 464
role in depression treatment 667–668
role in depression management 526
structure changes in China 738
depression in South Asia 731
support
dementia care in South Asia 732
in depression, ethnic groups 520
lacking, depression associated 520
see also family caregivers
Family Caregiver Alliance 422, 424
family caregivers 91, 415–420
assessment (health/stress levels) 416–417
diverse ethnic groups 417
domains to assess 416–417
best practices for supporting 417–418
evidence-based treatments 417–418
individualization 417, 418
multi-component treatments 418
programmes 418, 419
care recipient’s behavioural impairments 830, 832
definition 829
dementia vs non-dementia 830
ethnic groups and cultural diversity 415–416, 417
health impact of caregiving 415, 830–831
anxiety 831
depression 830–831
mental health outcomes 415, 830–831
physical health outcomes 831
knowledge about dementia 416, 417
positive and negative outcomes 830
public policy and cost implications 829
relocating recipient to nursing homes 831–832
resources for 417
social support for 417
stress 415–416, 829, 830
assessment 416
factors affecting 415, 830
models 829–830
stressors 830
support groups 418–419
support services 418–419, 831–832
see also caregivers/carers
Family Caregivers Alliance 416
family history
Alzheimer’s disease 238, 246
bipolar disorder 577, 579
as dementia risk factor 209
depression 486–487, 568
FTD 353
psychiatric history-taking 110
Family Involvement in Care (FIC) 832
family psychoeducational programme, psychotic disorders 606
fast axonal transport (FAT), APP transport 291
fat, body, increase with age 56
fatigue syndrome see neuasthenia
[18F]FDDNP-PET 259–260, 264
fatigue syndrome see neuroasthenia
[18F]-FLAIR images 434
flupentixol, absorption 55
flashback episodes 640
flavonoids 199
flashbulb memories 62
‘fluid abilities’ 62
fluorine-18 28
18F-fluoro-2-deoxy-glucose (FDG)-PET see FDG-PET scans
flutamide 199
fluoxetine in anxiety 628
in depression 538
in dysthymia 498
with rivastigmine 308
flupentixol, absorption 55
fluvonoxamine
in Alzheimer’s disease 319
in anxiety 628
in treatment-resistant depression 539
focal psychotherapy, adjustment disorder 642
folate deficiency 123
dementia aetiology 723
folate supplements 404, 407
Alzheimer’s disease 308
follicle-stimulating hormone (FSH) 46
food intake
alcohol abuse and 666
reduced, in dementia 764
see also diet; nutrition
forensic history, psychiatric history-taking 112
forensic psychiatrists 696, 697, 698
forgetting, age-related 499
Forkhead transcription factors 53
forward-digit span 131
‘Foundation’ Trusts 747
FOX03A gene 53
FP-CIT 366
fractional anisotropy 18, 20, 21
white-matter lesions in depression 491
frailty 66, 196
frailty index 66
France
depression prevalence 480
palliative care 838
free radicals 282
Freud, Sigmund 611, 633, 636, 650
frontal ageing hypothesis 61
frontal brain, volume reduction in normal ageing 17
frontal lobe
executive functioning 234
NAA decrease in normal ageing 447
frontal lobe dementia, forensic history and offence 112
frontal lobe lesions 37
frontolimbic region, fMRI activation, depression 491
frontotemporal dementia (FTD) 348
behavioural variant (bvFTD) 348
Addenbrooke’s Cognitive Assessment 131
age of onset 348
behavioural changes 130, 235
classification, DSM-IV-TR 201
clinical presentation 348–349
evaluation, diagnosis and imaging 30, 31, 350–351
incidence 348
left-sided atrophy 350
memory impairment not main symptom 204, 348
mutations 127, 353
pathology and neurogenetics 351–353
right temporal variant 132
brain functional changes 30, 350
cognitive impairment, personality disorders vs 657
learning disability with 689
magnetic resonance spectroscopy 451
offenders 696
as a proteinopathy (tau) 377
treatment 353
effect on brain function 32
frontotemporal dementia (FTD) syndromes 348–359
behavioural variant (bvFTD) see
frontotemporal dementia (FTD)
clinical evaluation and diagnosis 350–351
clinical features 348–350
course and management 353
FTDP-IF 353
FTDP-MND 353
FTDP-NT 353
FTDP-U 353
FTDP-UPS 353
histopathology of variants 352
pathology and neurogenetics 351–353
PNFA see progressive non-fluent aphasia (PNFA)
semantic dementia see semantic dementia (SD)
variants, relationship between 351–352
frontotemporal lobar degenerations 351
asymmetric atrophy, progressive
non-fluent aphasia (PNFA) 349
brain functional changes 30
F-spondin 293
functional abilities 176–182
age of onset of condition affecting 178
in Alzheimer’s disease 227
improvement (non-pharmacological interventions) 326
assessment 176–177
by family and clinicians 177
measures/rating scales 179–181
normative basis 176
preference-weighted approaches 176–177
‘core’ set 176
cultural factors affecting 178
decision-making capacity 177
environment affecting 178
impaired see functional decline/changes
influences affecting 177–178
‘recovery’ 177
social functioning 177
see also activities of daily living (ADL);
functional capacity; functional health status; life skills
functional aging 65–69
concept development 66
see also functional health status
Functional Assessment Staging procedure (FAST) 162, 166
advantages 166
as Medicare ‘gold standard’ 166
MMSE relationship 166
neuronal number decline 166, 167
time course of changes (normal to AD) 163
functional capacity 176
impaired see functional decline/changes
neuropsychological performance 179
see also functional abilities
functional compensation theory 438–439, 440, 441
functional decline/changes 30–32
adaptation and compensation 29
Alzheimer’s disease 29–30
frontotemporal dementia 30
frontotemporal lobar degenerations 30
Lewy-body associated disorders 30
mild cognitive impairment 29–30
neurodegenerative disorders 29–30
non-fluent progressive aphasia (NFPA) 30
normal ageing 29
semantic dementia 30
functional disability, model 178–179
functional disorders
community mental health team management 756
day hospitals 754
treated in private psychiatric hospitals
(US) 796
functional health status 65–67
cognitive function 66
factors affecting 66–67
frailty 66
long-term trends and policy implications 67
performance measures 66
self-reported 66
see also disability; functional abilities
functional imaging 28–35, 36
benefits 28
clinical applications 32
depression (geriatric) 491–492
frontotemporal dementia 350
MRI see functional MRI (fMRI)
techniques 28–29
functional limitation, definition 66
activation, definition 438
activation in MTL
changes in AD 439–440
changes in MCI 440–441
normal ageing 439
see also medial temporal lobe (MTL) in AD 439–440
advantages 437
applications 435, 437
blocked and event-related designs 435
dehystrogenization 438, 439
in depression 491
hyperactivation in MTL 441, 442
hypoposition in MTL 441, 442
methodological challenges in older people 435
neural networks supporting memory function 439
neural ageing 438–439
pharmacological, drug efficacy in AD/MCI 442
physiological basis 437–438
resting state (rs-fMRI) 32, 439
task-related 437
functional neuroimaging see functional imaging
functional specialization studies 29
functional units, age-related loss 55
funding
behavioural management, in AD 327
geriatries psychiatrists’ training 858
mental health workforce study in US 858
NHS 747–748
rehabilitation 812, 813
research 8
short-termism 813
US geriatric mental health care see
Medicaid (US); Medicare (US)
see also cost(s)
GABA 36
in AD 296
delirium pathophysiology 197
magnetic resonance spectroscopy 446
gag reflex, testing 120
gait
assessment 121, 130
cerebrovascular disease 130
instability, Parkinson’s disease dementia 365
Lewy body dementias 365, 366
normal pressure hydrocephalus 130
Parkinson’s disease 130
galantamine 305
Alzheimer’s disease 296–297
cognitive benefits 305
donepezil comparison 306
dosing 305, 314
effect on brain function 32
Lewy body dementias 367–368
neuropsychiatric effects 308
side effects 305, 314, 368
gamma glutamyl transpeptidase (γGT) 123
gastric acid, secretion 55
gastrointestinal system, examination 119
gaze, supranuclear 133
gender
affective disorder risk 460
alcohol abuse, age of onset 674
alcohol use prevalence 672
Alzheimer’s disease risk 271
apoe and Alzheimer’s disease 245, 246, 271
benzodiazepine misuse 681
brain atrophy in alcohol abuse 379
coping abilities and resource deficits 466
dementia incidence, Lundby study 222, 223, 224
as dementia risk factor 209
depression aetiology 618, 719
depression prevalence 618
sociodemographic correlates (cross-cultural) 718
Down syndrome 282
social networks 719
SUBJECT INDEX

887

gериатрическое отделение (Англия) 749–752, 759
clinical guidelines 751
historical background 749
key components 750–751
long-stay beds 751
New Ways of Working 750
primary vs secondary care 749–750
specialist services 751
theoretical basis 749
see also old age psychiatry development (UK)
Geriatric Research, Education, and Clinical Centers (GRECC) 422, 423–424
geriiatrics, development 7
Germany
co-ordination and management 46
palliative care 838
Gerstmann–Sträussler–Scheinker Disease 376
ghrelin 45
ghrelin analogue 46
Ginkgo biloba 308
adverse effects 403, 404
memory enhancement 403, 407
use in China 738
glaucoma, ECT treatment 531
glial cell-derived neurotrophic factor (GDNF) 42, 331
Global Assessment of Functioning (GAF) 179, 180
Global Burden of Disease 717, 721, 722
Global Deterioration Scale (GDS) 162, 164, 170
abridged scale 164
AD severity assessment 163, 164–166
advantages 165
Clinical Dementia Rating comparison 165
mild cognitive impairment 163, 164
MMSE relationship 165
reliability and validity 165
scoring 165
subjective cognitive impairment (SCI) 163, 164
time course of changes (normal to AD) 163
Global Mental Health Assessment Tool (GMHAT) 174, 175
glomerular filtration rate (GFR), drugs 56–57
glucocebrodiosidase (GBA) 364
deficiency 364
GBA gene mutations 367
‘glucocorticoid cascade’ 273
glucocebrodiosidosis, AD risk and 273
glucose 258–259
blood
control, delirium pathophysiology 197
cerebral metabolism
FDG-PET scans 258–259
PET studies 258
glucocorticoids, AD risk and 273
‘glucocorticoid cascade’ 273
glucocerebrosidase (GBA) 364
glomerular filtration rate (GFR), drugs 56
glutamate
Alzheimer’s disease 296, 307
delirium pathophysiology 197
excitotoxicity 307
recycling 28
role/functions 296
uptake change, calcium homeostasis
abnormality 292
glutamate/glutamine magnetic resonance spectroscopy 446
Alzheimer’s disease 451
depression 448, 449
memantine effect 451
glutamatergic deficit, in AD 296, 297
glutathione S-transferase (GST) 405
glycaemic control, delirium pathophysiology 197
glycogen synthase kinase 3 (GSK-3) 292, 293, 579, 583
GMS-AGECAT 479
anxiety prevalence 620
depression prevalence in Africa 482, 483
depression prevalence in Asia 482, 483
depression prevalence in Europe 479, 480, 481
GMS-HAS-AGECAT package 174–175
Gold Standard Framework 839–840
gonadotrophin-releasing hormone (GnRH) 46
go-no-go test 133
Goodmayes Hospital 7
Gospel Oak study 618, 619, 719
go-no-go test 133
Goodmayes Hospital 7
Gospel Oak study 618, 619, 719
graduates (mental health problems) 814
growth hormone-releasing hormone (GHRH) 197
halothane 822
Hamilton Rating Scale for Depression (HRS-D) 152, 497
haloperidol
in Alzheimer’s disease 314
cardiac effects 125
in delirium 198, 199
Hashimoto’s thyroiditis, investigations 124
Hayflick limit 52
head trauma, dementia risk factor 210
health
dimensions 741
markers, changes with age 87–88
subjective rating, depression and 509
Health and Social Security, Department of (UK) 746
health and social services, in UK see UK
Healthcare Commission 747
Health Care of the Elderly, development 8
health economics 90–96
bootstrapping 92, 93, 94
costs see cost(s)
mentalt disorders 92
informal care costs 91–92
modelling approaches 94
outcome measures 92–93
pharmacoeconomics and programmes 94
modelling approaches 94
resource utilization and costing 90
societal perspective 90
study types 90–91
see also cost(s); expenditure on health
health insurance, in US 782
see also Medicaid (US); Medicare (US)
health maintenance organizations (HMOs) 777–778
health-related quality of life (HRQoL) 92, 183–184
measurement 184, 189
see also quality of life (QoL) measures
use of proxies in dementia 92, 185
health status
measuring, in older people 85–86
Guthrie Trust Witness Seminar 861
haematological investigations 122–123
haematopoietic stem cells 335
hallucinations 114–115
Alzheimer’s disease 229–230, 312, 324
drug management see antipsychotic
drugs non-pharmacological management 326–327
auditory see auditory hallucinations
CBT outcome 606
delirium 195
in depression 566
pleasant 327
schizophrenia 596
visual see visual hallucinations
haloperidol
in Alzheimer’s disease 314
cardiac effects 125
in delirium 198, 199
halothane 822
Hamilton Rating Scale for Depression (HRS-D) 152, 497
hands, examination 118, 119
happiness, lack, depression 505
HAROLD (hemispheric asymmetry
reduction in older adults) phenomenon 29, 37, 439
Hashimoto’s thyroiditis, investigations 124
Hayflick limit 52
head trauma, dementia risk factor 210
health
dimensions 741
markers, changes with age 87–88
subjective rating, depression and 509
Health and Social Security, Department of (UK) 746
health and social services, in UK see UK
Healthcare Commission 747
Health Care of the Elderly, development 8
health economics 90–96
bootstrapping 92, 93, 94
costs see cost(s)
mental disorders 92
informal care costs 91–92
modelling approaches 94
outcome measures 92–93
pharmacoeconomics and programmes 94
modelling approaches 94
resource utilization and costing 90
societal perspective 90
study types 90–91
see also cost(s); expenditure on health
health insurance, in US 782
see also Medicaid (US); Medicare (US)
health maintenance organizations (HMOs) 777–778
health-related quality of life (HRQoL) 92, 183–184
measurement 184, 189
see also quality of life (QoL) measures
use of proxies in dementia 92, 185
health status
measuring, in older people 85–86
### SUBJECT INDEX

- **International Study of Postoperative Cognitive Dysfunction (ISPOCD) continued**
  - advantages 820
  - ISPOCD1 818, 819–820
  - ISPOCD2 820.
- internet-based cognitive-behavioural therapy (CBT) 846
- interpersonal problems, in depression 546–547
- interpersonal psychotherapy (IPT) 546–547
- case example 547
- general hospitals 806
- dysthymia 549
- efficacy 547
- MTL LD trials 547–548
- treatment strategies 547
- interview
- physical examination 118
- psychiatric history-taking 109
- intestinal permeability 55
- intraneuronal inclusions, in FTD 351
- investigations 122–128
- biochemistry 123–124, 345
- ECG 125–126
- genetic 127
- haematological 122–123
- indications 123
- legal considerations 127
- mandated 122, 123
- microbiology 124
- primary (‘routine’) 122, 123
- radiology 124
- relevance of abnormal tests 122
- secondary 122, 123
- specialized blood tests 124
- various/specific 127
- involutional melancholia 5, 592
- involutional paranoid state 592
- iodine deficiency 723
- IQ
  - assessment 137–138
  - measurement 135
  - see also intelligence
- IQCODE 143, 147–151
  - administration 147–148
  - applications 149–150
  - bias and limitations 149
  - development 147
  - MMSE comparison 148, 149
  - psychometric characteristics 149
  - scoring 147
  - as self-report questionnaire (IQCODE-SR) 149–150
  - short version 147, 149
  - long version vs, in dementia 148, 149
  - validation against clinical diagnosis 149
  - validation against neuropathology/neuroimaging 149
  - versions and languages 147
- iron
  - accumulation in grey matter, in ageing 21–22
  - deposition, sites 22
  - measurement/assessment 21, 22, 124
  - metabolism changes in AD 301
  - Islam 715, 741
  - isoflurane 821, 822
  - isolation (social), late-onset schizophrenia 601, 604
  - isotropic movement 18
  - Japan, coping abilities and environmental factors 466
  - jaundice, in physical examination 119
  - J-coupled point-resolved spectroscopy (JPRESS), 2D 451
  - judgement, impaired 204
  - jugular venous pressure (JVP), in examination 119
  - justice, principle of 766
  - Kahn’s three-factor biomedical model 72
  - Katz activities of daily living (ADL) 179, 180
  - see also activities of daily living (ADL)
  - kidney, drug clearance 56–57
  - kinesin-1 292
  - kinesin-1 light chains (KLC) 292
  - Kitwood, Tom 157
  - Klotho gene 52
  - Klüver–Bucy syndrome 431
  - Kraepelin, Emil 5, 502, 591, 596
  - kuru 372–373
  - plaques 375
  - laboratory tests, depressive syndromes 569, 570
  - lamotrigine, bipolar disorder 582
  - maintenance therapy 583
  - language
    - assessment 132, 138, 391
    - barriers, ethnic groups 714, 715
    - deficits
      - Alzheimer’s disease 226–227, 393
      - primary progressive aphasia (PPA) 113
    - see also speech
  - Lasting Power of Attorney (LPA) 111, 841, 842, 853
  - property and finance 853
  - welfare 853
  - lateral parietal region, deactivation (fMRI) for memory encoding 439
  - Latin America, dementia prevalence 721
  - laughing, pathological 578
  - Lausanne statement 861, 862
  - law (mental health) (UK) 850–853
  - development/evolution 850–851
  - investigations and mental capacity 127
  - Mental Capacity Act 2005 858
  - mental health association (incidence) 218
  - deposition 363, 365
  - development in transplanted neurons 331
  - Lewy body dementia (LBD) 363, 365
  - as neuroprotective response 363
  - Parkinson’s disease 360
  - Lewy Body Dementia Association 367, 422
  - Lewy body dementia 360–371
  - aetiology 363–364
  - classification 360–363
  - summary/key points 363
  - clinical diagnosis 366
  - clinical features 364–366
  - course and prognosis 367
  - differential diagnosis 363, 366
  - schizophrenia 600
  - diseases included 363
  - DLB see dementia with Lewy bodies (DLB)
  - D LB vs P DD 363
  - epidemiology 364
  - genetics 367
  - investigations and biomarkers 366–367
  - EEG 126
  - magnetic resonance spectroscopy 451
  - learning disability 689
  - elder abuse and 836
  - four principles 766–767
  - see also ethics/ethical issues
  - lead, levels in AD 301
  - learned helplessness model 325
  - legal and ethical issues 766–769
  - law and ethics 766–769
  - linear discriminant analysis (LDA) 149
  - law (mental health) (US), Medicare welfare 853
  - property and finance 853
  - legal issues see entries beginning law
  - leisure activities 850–851
  - see also activities
  - lentivirus-based vectors 336
  - lesbian, gay and bisexual (LGB) people
    - discrimination against 76
    - mental health issues 75
    - older people 76
  - leukencephalopathy, toxic 380
  - levodopa, depression in Parkinson’s disease 475
  - Levy, Raymond 13
  - Lewis, Professor Aubrey 7, 12, 13
  - Lewis bodies 360
  - cortical 360
  - dementia association (incidence) 218
  - deposition 363, 365
  - development in transplanted neurons 331
  - Lewy body dementia (LBD) 365
  - as neuroprotective response 363
  - Parkinson’s disease 360
  - Lewy Body Dementia Association 367, 422
  - Lewy body dementia 360–371
  - aetiology 363–364
  - classification 360–363
  - summary/key points 363
  - clinical diagnosis 366
  - clinical features 364–366
  - course and prognosis 367
  - differential diagnosis 363, 366
  - schizophrenia 600
  - diseases included 363
  - DLB see dementia with Lewy bodies (DLB)
  - D LB vs P DD 363
  - epidemiology 364
  - genetics 367
  - investigations and biomarkers 366–367
  - EEG 126
  - magnetic resonance spectroscopy 451
  - learning disability 689
- learning disability 689–693
  - ageing and social needs 691–692
  - dementia 689–690
  - clinical features 691
  - diagnosis 690
  - management 690
  - mental illness in 689
  - diagnostic barriers 689
  - palliative care 692
  - physical illness with 690–691
  - prevalence 689
  - services for 692
  - see also Down syndrome
  - learning theory 543
  - legal issues see entries beginning law
  - leisure activities 850–851
  - see also activities
  - lentivirus-based vectors 336
  - lesbian, gay and bisexual (LGB) people
    - discrimination against 76
    - mental health issues 75
    - older people 76
  - leukencephalopathy, toxic 380
  - levodopa, depression in Parkinson’s disease 475
  - Levy, Raymond 13
  - Lewis, Professor Aubrey 7, 12, 13
  - Lewy bodies 360
  - cortical 360
  - dementia association (incidence) 218
  - deposition 363, 365
  - development in transplanted neurons 331
  - Lewy body dementia (LBD) 363, 365
  - as neuroprotective response 363
  - Parkinson’s disease 360
  - Lewy Body Dementia Association 367, 422
  - Lewy body dementia 360–371
  - aetiology 363–364
  - classification 360–363
  - summary/key points 363
  - clinical diagnosis 366
  - clinical features 364–366
  - course and prognosis 367
  - differential diagnosis 363, 366
  - schizophrenia 600
  - diseases included 363
  - DLB see dementia with Lewy bodies (DLB)
  - DLB vs PDD 363
  - epidemiology 364
  - genetics 367
  - investigations and biomarkers 366–367
  - EEG 126
  - magnetic resonance spectroscopy 451
  - learning disability 689
Lundby study continued 222
Lund Longitudinal Dementia study 300
luteinizing hormone (LH) 46
magnetization transfer imaging 47
magnetic resonance imaging (MRI) 125, see MADRS
madhouses 745
macular degeneration 845
MacArthur Foundation 70, 71
macrostructural changes, normal ageing 17, 36
macular degeneration 845
madhouses 745
MADRS see Montgomery Asberg Depression Rating Scale (MADRS)
magnetic resonance imaging (MRI) 125, 435
1.5T, 3T vs 7T image differences 434
alcoholic dementia 379
Alzheimer’s disease 301
bipolar disorder 578
brain volume reductions, depression 468–490
CJD 375
cortical thickness mapping 262
cryptococcosis (CNS) 430
in depression 489–490, 490–491
echo time (TE) 434
‘fluid void’ sign 125
frontotemporal dementia 350, 351
functional see functional MRI (fMRI)
microstructural white-matter lesions 490–491
normal ageing
iron/ferritin accumulation 21–22
macrostructural changes 17
structural–functional correlations 17
perfusion 435
principles and technique 434
proton 446, 447
repetition time (TR) 434
structural 434
T1 and T2 relaxation times 434
vascular depression 468
white matter lesions 344
magnetic resonance spectroscopy (MRS) 446–454
31P-MRS 446, 448
in depression 449–450
Alzheimer’s disease 450–451
bipolar disorder 449, 450
depression (geriatric) 448–450, 492
frontotemporal dementia 451
Lewy body dementia 451
mild cognitive impairment 450
normal ageing 446–448
nuclear isotopes used 446
principles 446
proton see proton magnetic resonance spectroscopy
strengths and limitations 451
two-dimensional 451
vascular dementia 451
magnetization transfer imaging, depression (geriatric) 491
magnetization transfer ratio (MTR), depression (geriatric) 491
magnetoencephalography (MEG) rhythms in AD 38–39
normal ageing 38
Maintenance Therapies for Late Life Depression (MTLLD1 and MTLLDII) trials 547–548
major depression see depression (geriatric), major
malabsorption, alcohol abuse and 666
malnutrition 845
alcohol abuse contributing to 666
in hospitals and care homes 824
management 826
mental illness and 825
physical/mental consequences 824
prevention 825–826
risk groups 824, 825
in UK, USA, Australia 824
Malnutrition Universal Screening Tool 825
managed care companies 778, 782
managed care programmes 770, 771, 778, 782
mania 576–588, 600
acute, treatment 580–582
age of onset 576–577
bi-modality in age of onset 573
clinical features and health service usage 579
cognitive impairment 578–579
in dementia 574
early- vs late-onset 574
ECT 531
epidemiology 573, 576, 600
late-onset 500
treatment 539
management 580–583
mortality 576
neuroimaging 578
pathogenesis 579
rapid cycling 458
right-sided lesions and 578
risk factors 573–574
secondary 574, 576, 578
speech in 113
stroke association 578–579
subcortical hyperintensities 574
uniportal 577
vascular subtype 578, 579
see also bipolar disorder
manic episodes
classification 457
irritable/angry 457
MAOIs see monoamine oxidase inhibitors (MAOIs)
MAPT see microtubule-associated protein tau (MAPT)
MAPT gene
knock-out mice 254
mutations 240, 353
marital status, depression prevalence 618
mesturbation 709
Maudsley Hospital 12, 13
MCI see mild cognitive impairment (MCI)
McLean Hospital (Massachusetts, USA) 798, 799, 800
discharge diagnosis 800
partial hospital programme 800–801
meals, presentation and supervision 825
means-testing 750, 751, 759
Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) 176
medial parietal region, deactivation (fMRI) for memory encoding 439
changes in AD 440
changes in MCI 440
medial temporal lobe (MTL)
fMRI activity decreased in AD 439–440
memory function 439
normal ageing 439
suppression in normal memory encoding 440
hyperactivation Alzheimer’s disease 440
mild cognitive impairment 441, 442
hypoaivation, in mild cognitive impairment 441, 442
volume reduction in AD 17
Medicaid (US) 770
beneficiaries and expenditures 772
expenditure on home/community-based services 773
expenditure on nursing homes 773
dually eligible Medicare beneficiaries with 771–772
expenditure on schizophrenia 774
medical history 117
‘Medical Home’ (US) 773
medical hospitals see general hospitals
medical insurance 745
US 782
see also Medicaid (US); Medicare (US)
‘medically unexplained symptoms’ 636
clinical presentation 637
in general hospitals 806–807
management approach 638–639
prevalence 637
treatment 639
see also somatoform disorders
Medical Outcomes Study (MOS), SF-36 179, 180
medical psychiatric inpatient unit (US) 785–789
administration 785–788
admission criteria/priority system 786
clinical programming 787
daily schedule/programme 787
design/structure/layout 785–786
factors influencing re-admission 788
factors influencing stay duration 788
unit operations 787
clinical issues 788–789
inpatient evaluation/management 788–789
conditions treated in 785, 788
costs and viability 787
diagnostic facilities 786
education (psychiatric) 789
inappropriate admissions to 786
multidisciplinary team 786–787, 788, 789
neuropsychiatric effects 307–308, 319
prescribing and monitoring 307
rational and cognitive effects 307
side effects 305, 307, 314
memapsin see BACE1
memories
of adolescence/young adulthood 62
flashbulb 62
memory 397
age-related decline 61–62
assessment 131, 138, 390, 391
consolidation, impairment in AD 393
cueing, failure to benefit in AD 393
declarative 397
deicits see memory impairment/deficits
encoding, medial/lateral parietal region
deactivation 439
episodic see episodic memory
formation
adult neurogenesis role 332
medial temporal lobe activation 439
levels of processing approach 397
long-term 226, 390
neural networks supporting 439
non-declarative 397
procedural, training 326
processing, reduced depth, with age 61
prospective 62
recall, Alzheimer’s disease 226, 393
retention, assessment 390
self-perception 397
semantic see semantic memory
training see memory training
types 138, 397
working see working memory
memory books 326
memory clinics 8
memory clues 226
memory disorder clinics 801
Memory Fitness programme 399
memory group therapy 798
memory impairment/deficits
age-related decline 17, 61–62
alcohol misuse and 111
Alzheimer’s disease 17, 204, 226, 393
impaired neurogenesis and 291
Aβ misfolding and oligomerization and
290–291
dementia 233
dissociative amnesia vs 643
dementia, amnestic syndrome and delirium
cluster 107
demenias not presenting with 204, 208
depression 394
ECT side effect 533
general slowing theory and 64
herpes simplex encephalitis and 431
history-taking 110
normal aging 17
as presenting complaint 129
recall/use old vs new information 62
SPECT imaging 257–258
memory improvement
complementary/alternative medicine see
complementary and alternative
medicine (CAM)
culturally based healing arts 405–406
diet/nutritional supplements 404
herbal preparations 403–404
SAMe 404–405
see also memory training
memory training 397–402
AD management 326
approaches 398
biofeedback 406, 407
computer-assisted interventions 398–399
factors influencing 398
long-term outcomes 399
multifactorial programmes 399
pretraining 398
see also cognitive training
men
age-related hormonal changes 706
sexual disorders 708
meningioma 386
meningitis
HSV, 429
tuberculous 426
menopause 46, 406
mental abilities see cognition/cognitive
abilities
mental capacity
investigations and legal issues 127
lack, decision-making 767, 769
see also mental incapacity
Mental Capacity Act (2005) 10, 746, 761,
841, 842, 852–853
development 851
on investigations/testing 127
principles 852
mental deterioration in elderly, 19th century
views 4
mental disorders
adverse outcome potential in long-term
care 795
ageing not associated with increased risk
97
definition, Mental Health Act 2007 852
in Down syndrome 283
emotional distress distinction 97
genetic and social causes 97–98
importance of sense of purpose 98
learning disability with 689
malnutrition and 825–826
older people less likely to seek help 99
prevalence/incidence in general hospitals
803
religion/spirituality benefits 98
risk indicators 847
social causation 97–98
social selection 97, 98
somatoform presentation 638
treatment 638
treatment, shaped by social factors 99
mental health 717
assessment, ethnic groups 713
economics see health economics
in family caregivers 830–831
interventions, goal 176
prevalence changes 88
problems in primary care 524
mood stabilizers
motor threshold, reduced in AD 37
motor neuron disease (MND) 349
motor-evoked potentials (MEPs) 37
morphine
morbidity, compression 67
morals, practical application 766–768
moral dilemmas 766–767
mood disorders
Alzheimer’s disease 320
acute mania 580–581
Alzheimer’s disease 252–256, 272
pharmacodynamics 58
metabolites 56
bipolar disorder 582, 583
bipolar disorder; depression see also substance-induced 566
secondary 458
recurrent 458
in Parkinson’s disease multifactorial inheritance 460
late-life 460–461
assessment tests 392
depressed but not disordered 459
in Mental State Examination (MSE) 114
symptoms in AD 227–228
mood disorders
bipolar see bipolar disorder
causes 509
classification 457–459
dysthymia, classification 458–459
early-onset, genetic causes 461
ECT for 529–530
genetics 460–463
age-related variation, reasons 460
bipolar disorder 461
depression 461
increased phenocopy expression with age 460
mortality 460
in Parkinson’s disease see Parkinson’s disease (PD)
recurrent 458
secondary 458
substance-induced 566
treatment, in medical psychiatric inpatient unit 788
see also bipolar disorder; depression (geriatric); mania
mood stabilizers
acute mania 580–581
Alzheimer’s disease 320
dosage and side effects 314
bipolar disorder 582, 583
monitoring (serum levels) 126
moral dilemmas 766–767
morals, practical application 766–768
morbidity, compression 67
morphism
metabolites 56
pharmacodynamics 58
motor-evoked potentials (MEPs) 37
motor neuron disease (MND) 349
motor threshold, reduced in AD 37
mouse models
Alzheimer’s disease 252–256, 272
3XTg 292
advantages 255
APLP2 knockout 289
APP-deficient 289
APPswe 252, 253
CaMKIIα-tTA x tet-APPswe/ind 253, 254
conditional transgenic mice 253, 254
‘congenic’ strain 255
double transgenic mice 253
knockout 254
limitations 255
PDAPP model 252, 253, 272
PSEN1 mutations 242, 252
rTG3696AB 254
rTG4510 253, 254
Tg2576 272
triple transgenic mice 253
variability 255
knockin, PSEN1 mutations 242
knock-out 254
APP 252, 259
BACE1 254, 290
MAPT gene 254
PSEN1 mutations 242
mutations with altered life span 52
reduced DNA repair 52
transgenic 272
age-dependent behavioural deficits 255
amyloid beta (Aβ) amyloidosis 252, 254–255, 291
conditional 253, 254
tauopathy 252–253
triple 253, 254
movement, abnormal, in physical examination 118
movement disorders, sleep-related 702
[18F]MPPF-PET 260
MRI see magnetic resonance imaging (MRI)
MRS see magnetic resonance spectroscopy (MRS)
MTLLD1 and MTLLDII trials 547–548
Multidimensional Observation Scale of Elderly Subjects (MOSES) 179, 181
multidisciplinary team 753
community mental health teams 756
medical psychiatric inpatient unit 786–787
new ways of working by 756
primary care psychiatric hospitals (US) 797
in psychogeriatric services 750
in rehabilitation 811
team members 753
medical psychiatric inpatient unit 786–787
multifocal arteriosclerotic dementia 4
multi-infarct dementia 4
medical psychiatric inpatient unit 786–787
Myobacterium tuberculosis 4
myocardial infarction 4
myoclonus 133
myocardial infarction depression after 619
ECT cautions 531
silent 614
myoclonus 133
in CJD 377
mynoisotol abnormal levels, predementia phase 282
Down syndrome and 282
magnetic resonance spectroscopy 446
increased in AD 450
increased in depression 448
increased in diabetes 448–449
mild cognitive impairment 450
normal ageing 447
NAA (N-acetylaspartate), magnetic resonance spectroscopy 446
depressed 450–451
Alzheimer’s disease 450–451
depression 448, 449, 492
mild cognitive impairment 450
in normal ageing 447
lithium effect in bipolar disorder 583
naltrexone, in alcohol abuse 668
names, difficulty remembering 398, 439
naming tests 131, 132
napping 701
National Alliance for Caregiving 423, 424
National Alliance for the Mentally Ill (NAMI) 787
National Alzheimer’s Coordinating Center (NACC) 422, 423
National Association of Area Agencies on Aging (n4a) 422, 424
National Cell Repository for Alzheimer’s Disease (NCRAD) 422, 423
National Center on Caregiving (NCC) 424
National Council on Aging (NCOA) 423, 425
National Dementia Strategy (UK) 9–10, 751, 812, 813
aims/criteria 814
National Diet and Nutrition Survey (UK) 824, 825
National Epidemiologic Survey on Alcohol and Related Conditions (NESARC) 577, 671, 672, 673, 675, 676
National Family Caregivers Association (NFCA) 422, 424
National Health and Nutrition Surveys (US) 824
National Health Service (NHS) 7, 746
beds occupied by elderly people 803
bureaucracy 748
continuing care see NHS continuing care establishment 746
funding 747–748
geriatric psychiatrists role 862
internal market 746, 749
long-term care in dementia 749–750
malnutrition in hospitals 824
market forces and competition 746–747, 749
Next Stage Review 748
psychogeriatric services 749, 751
reforms (1974–1980s) 746
reforms (1997–2007) 747–748
reforming 749–750
malnutrition in hospitals 824
market forces and competition 746–747, 749
National Institute on Aging (NIA) (USA) 421, 422, 857
National Institute on Alcohol Abuse and Alcoholism (NIAAA) 673
National Institute for Health and Clinical Excellence (NICE) see NICE
National Institute of Mental Health (NIMH) 774
National Institute for Mental Health in England (NIMHE) 741
National Performance Framework 747
National Service Framework for Older People 59, 518, 525, 747, 854
key components 756
National Service Frameworks 751
National Survey of Psychiatric Morbidity (UK) 620
neuroendocrinology 45–50
neuritic plaques 287
neurite growth inhibitor (NOGO) 290
neurasthenia 613, 643–644, 739
neural stem cells (NSCs) 43, 291, 330, 332–334
adult 335
neural repair 330, 337–338
Netherlands
depression incidence 486
depression prevalence 480
neural reserves, AD risk 272
neural stem cells (NSCs) 43, 291, 330, 332–334
adult 335
either emerging 332
definition/description 332
foetal 335
niche see neurogenic stem cell niche
transplantation 334, 335
see also neurogenesis
neural transplantation 42, 43, 330, 334–335
clinical trial design 337
differentiation and integration problems 335
effect of 334–335
Huntington’s disease 331
Parkinson’s disease 331
safety concerns 335
neurasthenia 613, 643–644, 739
clinical features and differential diagnosis 644
treatment 644
neurite growth inhibitor (NOGO) 290
neuritic plaques 287
neocortex, dementia association 218
Neurobehavioral Rating Scale (NBRS) 312, 313
neuroblasts, committed, transplantation in Huntington’s disease 331
neurochemistry
Alzheimer’s disease 295–298, 299–300
acetylcholine 295, 299
GABA and somatostatin 296
glutamate 296
neurotransmitter receptors 296
noradrenaline 299–300
serotonin 296, 300
treatment based on 296–297
normal ageing 447
neurocognitive disorders 107
neurocognitive functioning, patterns in dementia 233–234
neurodegenerative disorders
CJD see Creutzfeldt–Jakob disease (CJD)
classification 108
eyerly detection, neuropsychological assessment trends 235
functional changes 29–30
individual variability and overlaps 108
neuroendocrinology 45–50
vascular disease and depression 470
neurofeedback, cognitive enhancement 406
neurofibrillary tangles 36, 287
age-related cognitive decline link 259, 295
Alzheimer’s disease 240
treatment target 309
conditional tau transgenic mice 253, 254
Down syndrome 281
tentorial cortex 295
[18F]FDDNP-PET imaging 259
in MCI 295
neocortex, dementia association 218
see also tau, hyperphosphorylation
neurofilamentopathies 108
neurogenesis 331–334
adult 43, 330, 332
background to 331–332
role in memory formation 332
sites 291, 332
cross-talk and effects 291
decline with age 291, 333
embryonic/postnatal, PS1 regulating 291
hippocampal 333, 334
impairment in AD 291, 334
psychiatric illness and 333
stroke and 334
see also neural stem cells (NSCs)
neurogenic signalling, PS1 role 291
neurogenesis
neurodegenerative disease 333–334
normal ageing 333
regulation 332–333
subventricular zone, impaired olfaction and 334
see also neural stem cells (NSCs); neurogenesis
neurohypophysis 47–48
neuroimaging 233, 490
alcoholic dementia 379
Alzheimer’s disease 301
cognitive ability decline studies 62
delirium 196
dementia diagnosis 125, 602
impact on epidemiology studies 211
in learning disability 690
depression 489–494, 496
3D brain mapping technique 490
functional imaging 491–492
methodological issues 490
microstructural imaging 490–491
regions of interest (ROIs) 489
volumetric studies 489–490
white matter hyperintensities 490–491
see also individual techniques
Down syndrome 282–283
functional see functional imaging
IQCODE validation against 149
metabolic/molecular scanning see positron emission tomography (PET); single photon emission computed tomography (SPECT)
normal ageing 438–439
structural
CT 433
normal ageing 17–27
white-matter lesions 344, 490–491
see also diffusion tensor imaging (DTI); magnetic resonance imaging (MRI)
vascular dementia 345
neuroinflammation, Down syndrome 282
neuroleptics see antipsychotic drugs
neurological examination 119–121
in bedside cognitive assessment 133, 137
behavioural variant (bvFTD) 349
importance 119
neuronal intermediate filament inclusion body disease 353
neuronal plasticity 36
see also neurogenesis
neuronal stem cells see neural stem cells (NSCs)
nurons
loss
[18F]MPPF-PET 260
FAST scale relationship 166
locus coeruleus, in AD 299
nucleus of Meynert, in AD 295
regeneration 332, 333
see also neural stem cells (NSCs)
volume decline, in normal ageing 447
neuropathology 287
Alzheimer’s disease 239–240
dementia 218
Down syndrome 281
IQCODE validation against 149
molecular, of AD see Alzheimer’s disease
neurophysiology of ageing (brain) 36–41
cortical excitability 37–38
EEG/MEG rhythms 38–39
transcranial magnetic stimulation studies 37
Neuropsychiatric Inventory (NPI) 227, 312, 313, 392
neuropsychiatric symptom rating scales 312, 313
neuropsychiatric symptoms (cognitive) see attention; cognition/cognitive abilities; executive function; memory; orientation (general)
neuropsychiatric symptoms (non-cognitive) 227
Alzheimer’s disease 226, 227–229
affective disturbances prominence 227–229
cholinesterase inhibitor effect 307–308, 318–319
costs related to 312
management see behavioural management, in AD
memantine effect 312, 313, 392
prevalence 228, 229
psychotic disturbance prominence 229–230
Lewy body dementias 364, 365
management in 368–369
see also antipsychotic drugs; behavioural disturbances
neuropsychiatry 788
overlap with medical/geriatric psychiatry 788
neuropsychological assessment 135–140
avoid medical procedures 135, 138–139
score calculation 139
summary, recommendation and feedback 139
time requirement 138
aims and scope 137–138, 233, 235, 389
profile of strengths/difficulties 136, 139
behavioural variant FTD 349
bipolar disorder 579
clinical (deficit-orientated) 135–137, 389–396
abnormal scores and premorbid ability 233
abnormal scores significance 234
cut-off scores 135, 136, 234
demographically adjusted scores 235
early detection of neurodegenerative disorder 235
factors affecting results 136, 235
normative data 135, 136, 233, 235
premorbid ability and test performance 234
singularity of domains from specific tests 234
time course of recovery in depression 234–235
uses, role and aims 233, 235

cognitive domains, tests used for 137–138, 389–396
attentional functions 138, 389–390
general orientation 389
intelligence 137–138, 390
cognitive domains assessed 389
dementia and Alzheimer’s disease 232–237, 393
misconceptions about 234–235
neurocognitive patterns 233–234
recent trends 235
depressive syndromes 568–569
diagnostic sensitivity improvement 235
ethnic groups 714
expectations about performance 136
Lewy body dementias 365
misconceptions about 234–235
neuroimaging impact 233
normal ageing changes vs deficits 137
pattern of scores 136–137
psychometric testing (population-based) 135, 232
standardized tests 135–137
repeating 137, 138
score expression 135–136
screening tests 137, 138
selection of 137
translation of tests 136
see also Mental State Examination (MSE)
neuropsychologists, private psychiatric hospitals (US) 797–798
neuropsychology 232
neuroregenerative drugs 337–338
neurorehabilitation, in dementia 813
neuroses 611
see also neurotic disorders
neurosyphilis 384, 428
meningovascular 428
neurotic disorders 640–646
AD risk, 273
classification and nosology 611–615
history of 611–612
ICD-10 vs DSM-IV 611–612, 613, 614
diagnosis
considerations in elderly people 613–614
multiaxial system 611
diagnostic features 612–613
Lundby study 222
see also obsessive-compulsive disorder
(OCD); somatoform disorders; other specific disorders
neurotic personality style, somatoform presentation 638
neurotransmitters, in AD 295–296, 299–300
see also neurotransmitters
NHS continuing care 759–765
basic activities of daily living, support 761
behavioural and psychological symptoms management 762–763
case examples 761, 762, 763
closures, transfer of patients 760
‘domus care’ 760
end-of-life care 764–765
family disengagement 764
focus on rehabilitation 760
legal frameworks 761
legal status 759
maintaining mobility/minimizing falls 763
models 759–760
mortality rates 760
nutrition and feeding 764
pain assessment/treatment 763
physical health needs 763–764
purpose-built units 759–760
quality of care and audit 760
reducing/dismantling 759
relocation, impact on patients 760
requirements for high quality care 760
review panels and review of patient 759
selection of patients 760
skin care 764
social needs 759–762
NHS Trusts 746, 747
nicotinic (NCT) 289
NICE guidance 747
CBT in psychotic disorders 605
depression management 525
mindfulness-based cognitive therapy 546
in Parkinson’s disease 474
electroconvulsive therapy (ECT) 530, 531, 533
OCD treatment 633
palliative care and spiritual support 741
repetitive transcranial magnetic stimulation (rTMS) 534
specialist assessment in dementia 806
NICE Reviews, of ECT 530, 531
nicotinic receptors, reduced in AD 296
nigrostriatal system
degeneration in PD 331
regeneration and repair 42, 43
nimodipine 470
NINCDS-ADRDA, dementia classification 201, 202
NINDS-AIREN criteria
mixed dementia 345
vascular dementia 342–343
NMDA receptor 296
antagonist (memantine) action 297, 307
stimulation, delirium pathophysiology 197
Noggin 337
NOGO (neurite growth inhibitor) 290
nominal dysphasia 113
non-communicable disease (NCD) 717, 723
non-compliance
cognitive training 400
depression associated 508
non-fluent progressive aphasia (NFPA), brain functional changes 30
non-maleficence 766
nonproline-directed protein kinases (NPDPKs) 292
non-rapid eye movement (NREM) sleep 700, 701, 702
non-steroidal anti-inflammatory drugs (NSAIDs)
AD risk and prevention 274
adverse events 58
noradrenaline and specific serotonin antidepressant (NaSSA)
anxiety/anxiety disorders 628
depression in Parkinson’s disease 475
noradrenergic system
in AD 299–300
cell loss in AD 299
hyperactivity in advanced AD 299
in Lewy body dementias 364
normal ageing 17–27
adaptation and compensation 29
AD differential diagnosis 389
cognitive decline 392–393
vs abnormal cognitive impairment 137, 209, 392–393
cortical excitability 37
depression viewed as part of 518, 520
EEG/MEG 38
executive function decline 227
functional changes 29
GDS/FAST and CDR scales 163
loss of hemispheric asymmetry activation 439
macrostructural changes 17
magnetic resonance spectroscopy 446–448
microstructural changes (DTI) 18
longitudinal studies 21
neuroendocrinology 45–50
normal ageing continued
neurogenic stem cell niche 333
neuroimaging 438–439
neuronal numbers, FAST and 166, 167
quantitative fibre tracking 18–20, 21
tau and tangle pathology 295
white matter structure--function
relationships 21
working memory deficits 17
see also successful ageing
normal pressure hydrocephalus (NPH) 384, 386
gait 130
reversible dementia 385, 386
North America, depression prevalence 480, 482, 483
nortriptyline
after ECT 530
in anxiety/anxiety disorders 628
depression treatment 537, 538
relapse/recurrence reduced by 539
effect on brain function 32
nosology see entries beginning DSM or ICD; specific disorders
NREM sleep 700, 701, 702
nucleoside triphosphate (NTP), in
NREM sleep 700, 701, 702
nutritional supplements
nutritional state 825–828
nutritional deficiencies 825, 826, 827
dementia aetiology 723
management 826
nutritional deprivation
AD risk 274
dementia aetiology 723
nutritional state 824–828
nutritional supplements
AD improvement 301
AD prevention 275
memory enhancement 404
nystagmus 133

obesity 824
AD risk 273
in learning disability 691
SUBJECT INDEX

Parkinson’s disease (PD) 364, 365
  management 474–477, 567
  as premorbid sign 473–474
  rating scales 473
  screening 476, 477
  gait 130
  Lewy bodies 360
  mood disorders 473–478
  mortality 474
  neural transplants 331
  non-motor symptoms 473
  palliative care 838
  prevalence 473
  as a proteinopathy (α-synuclein) 377
  psychosis 600
  risk factors, antidepressant therapy and
  depression 474
  severity, depression relationship 474
  subventricular zone thinning 334
  α-synuclein mutation 127
  tremor 133
  visual hallucinations 600
  Parkinson’s disease (with) dementia (PDD)
  360
  brain functional changes 30
  classification 361
  clinical diagnosis 366
  clinical features 361, 364–366
  differential diagnosis 366
  DLB 363
  epidemiology 208, 364
  investigations and biomarkers 366–367
  management 368, 369
  possible, diagnosis 361, 362
  probable, diagnosis 361, 362
  risk factors 364
  see also Lewy body dementia
  paroxetine
  in depression 538, 539
  side effects 628
  PASA (posterior-anterior shift in ageing)
  phenomenon 29
  passivity phenomena 114
  pathological laughing 578
  Patient Reported Outcomes Measurement
  Information System (PROMIS) 176
  penile stimulation 706–707
  perception, in Mental State Examination
  (MSE) 114–115
  percutaneous endoscopic gastrostomy (PEG)
  826, 827, 838
  Percy Commission (1957) 850, 851
  perforant pathway 233
  perfusion MRI 435
  periodic limb movement disorder (PLMD)
  702
  periodic limb movements in sleep (PLMS)
  702
  personal care/hygiene
  aggression during assistance 761, 762
  decline 113
  problems, in FTD 348
  personal development plans (PDPs) 856
  personal history, in psychiatric
  history-taking 110–111
  personality
  age-related changes 495
  assessment tests 392
  changes, cognitive assessment 129–130
  premorbid, in psychotic disorders 601,
  in psychiatric history-taking 111
  personality disorders 601, 649–654,
  655–661
  aetiology 649–650
  genetic factors 650
  psychosocial factors 650
  ageing process altering pathology
  656–657
  antisocial 656
  assessment measures 656
  borderline see borderline personality
  disorder (BPD)
  classification 611, 649, 651, 655, 657
  DSM-IV 107, 649, 655, 657
  ICD-10 106
  Cluster B (‘high-energy’) 651, 652
  Cluster C (‘low-energy’) 651
  cognitive distortions in 650
  comorbidity 651, 655, 657
  decline with age 652
  definition 649
  depression with 498, 651–652, 655
  see also DSM-IV, Axis I disorders
diagnosis and identification 655
  barriers to 655–656
  problems and misinterpretation
  650–651, 656
  diagnostic criteria 656
  dialectical behaviour therapy 546, 658
  differential diagnosis 657
  epidemiology 651–652, 655
  summary 652
  geriatric variants 652
  histrionic 643, 649
  impact on psychotherapy 658–659
  importance in older people 649
  late emergence of symptoms 649, 651
  long-term care (US) 793
  management approaches 658
  mature and immature types 656
  obsessional 632
  in offenders 696
  paranoid see paranoid personality disorder
  prognosis 652
  stability/change over life span 656
  stigma 656
  suicidal behaviour 560
treatment
  psychopharmacological 659–660
  psychotherapy 658–659
  see also psychological therapy
  personality styles, somatoform presentation
  638
  personality traits
  adaptive and maladaptive 649
  AD risk 273
  context of expression 649
  major, five-factor model (FFM) 656
  suicidal behaviour 560
  temporal stability 656–657
personal safety, dementia patients 413
person-centred care 813
Alzheimer’s disease 325
at care homes 79, 80
Dementia Care Mapping (DCM) 157, 159
at home, dementia patients 812
long-term care focusing on 159
person-centred ethics 768–769
person-centredness 768
personhood 742
ethics and 768–769
pesticides, suicide in China 739
pet therapy, in AD management 325
phosphorus, 31P-MR spectroscopy
phosphodiesterase type 5 (PDE5) inhibitors
phonemic paraphasia 132
phenelzine 537, 628
pharmacology of ageing 55–59
PGRN gene 348
pet therapy, in AD management 325
person-centredness 768
person-centred ethics 768–769
person-centred care 813
pharmacological history, psychiatric
pharmacokinetics 55–57, 537, 679–680
pharmacogenetics, in AD 301
pharmacoeconomics 94
pharmacodynamics 57–58, 537
phantom boarder 229, 312
PHA-4 protein 53
depression with 763–764
dementia with 763–764
care 763–764
chronic, prevention of mental disorders in
bipolar disorder with 577–578
alcohol-related 665, 667, 675
bipolar disorder with 577–578
chronic, prevention of mental disorders in 845
dementia with 763–764
depression with 763–764
depression (geriatric), physical illness with
effect on sexuality 707
elderly offenders 697
impact on neurotic disorder diagnosis 614
inpatient management in US 797
see also medical psychiatric inpatient unit (US)
learning disability with 690–691
mental disorder co-morbidity
in general hospitals 803–809
South Asia 732
see also liaison psychiatry
psychiatric consultation indications 510
psychiatric disorders affecting 509–510
psychiatric symptoms 122, 643
suicidal behaviour 560–561
see also chronic illness
physical symptoms
due to psychological trauma 636, 637
unexplained see ‘medically unexplained’
symptoms’
physicians, primary care
private psychiatrists’ relationship (US) 781
see also general practitioners (GPs)
Pick, Arnold 348
Pick’s disease 348
4 Pillars of Alzheimer’s Prevention 424
pineal gland, age-related changes 48, 700
pituitary gland
anterior, age-related hormone changes 45–47
posterior, secreted substances 47–48
planter reflex (Babinski sign) 121
plasma proteins, drug binding 56
plasticity
neuronal 36
synaptic see synaptic plasticity
platelets
APP fragments 300
in depression 470
dysfunction 470
membrane fluidity (PMF) 300
POCD see postoperative cognitive dysfunction (POCD)
polyarteritis nodosa, investigations 124
polyarthritis nodosa, investigations 124
polyneuritis rheumatica, investigations 124
polypharmacy 58–59, 680
depression and 509, 511
minimization, anxiety treatment guidelines 629
polysonomography (PSG) 127, 701
polysubstance misuse 681–682
Poor Law (UK) 745
population sizes
research 821
postoperative delirium see delirium
post-stroke depression see stroke, depression after
post-traumatic stress disorder (PTSD) 641–642
bipolar disorder co-morbidity 577
chronic 641
classification 612, 640, 641
clinical features 641
delayed-onset 641
diagnosis and symptoms 614
differential diagnosis 640, 641–642
prevalence 620, 641
treatment 642
benzodiazepines 626
SSRIs 628
postural hypotension see orthostatic hypotension
potentially reversible causes of dementia
(PrD) 383
see also reversible dementias
pout reflex 133
poverty 745
depression aetiology 618
practice nurses, depression management in
ethnic groups 521, 522
Prader–Willi syndrome 691
pramipexole, depression in Parkinson’s disease 475
praxis
Alzheimer’s disease 227
assessment 132
prazosin, PTSD 642
Preadmission Screening and Annual Resident Reviews (PASARR) 792–793
isotopes/tracers 257, 258, 262
Lewy body dementias 366
limitations 259
[18F]FDNP-PET 259–260
[18F]FDDNP-PET 259–260, 264, 301, 350
principles and image acquisition 258
spatial resolution 258
SPECT comparison 257, 259
time-of-flight 258
positron emission tomography (PET)/MRI 258
Post, Felix 12–14
autobiographical account 12–13
commentary on 13–14
postconcussional syndromes 643
posterior–anterior shift in ageing (PASA) 439
posterior cingulate cortex 29, 30
in AD 29
Postgraduate Medical Education and Training Board (PMETB) 854, 855
post-hip fracture delirium see hip fracture
postoperative cognitive dysfunction (POCD) 818–821
definition 818, 819–820
hypoxaemia and hypotension role 818, 820
incidence at one week/three months 821
ISPOCD data 818, 819–820
as new disease vs unmasking of latent problem 821
postoperative delirium see delirium
post-stroke depression see stroke, depression after
post-traumatic stress disorder (PTSD) 641–642
bipolar disorder co-morbidity 577
chronic 641
classification 612, 640, 641
clinical features 641
delayed-onset 641
diagnosis and symptoms 614
differential diagnosis 640, 641–642
prevalence 620, 641
treatment 642
benzodiazepines 626
SSRIs 628
postural hypotension see orthostatic hypotension
potentially reversible causes of dementia
(PrD) 383
see also reversible dementias
pout reflex 133
poverty 745
depression aetiology 618
practice nurses, depression management in
ethnic groups 521, 522
Prader–Willi syndrome 691
pramipexole, depression in Parkinson’s disease 475
praxis
Alzheimer’s disease 227
assessment 132
prazosin, PTSD 642
Preadmission Screening and Annual Resident Reviews (PASARR) 792–793
isotopes/tracers 257, 258, 262
Lewy body dementias 366
limitations 259
[18F]FDNP-PET 259–260
[18F]FDDNP-PET 259–260, 264, 301, 350
principles and image acquisition 258
spatial resolution 258
SPECT comparison 257, 259
time-of-flight 258
positron emission tomography (PET)/MRI 258
Post, Felix 12–14
autobiographical account 12–13
commentary on 13–14
postconcussional syndromes 643
posterior–anterior shift in ageing (PASA) 439
posterior cingulate cortex 29, 30
in AD 29
Postgraduate Medical Education and Training Board (PMETB) 854, 855
post-hip fracture delirium see hip fracture
postoperative cognitive dysfunction (POCD) 818–821
definition 818, 819–820
hypoxaemia and hypotension role 818, 820
incidence at one week/three months 821
ISPOCD data 818, 819–820
as new disease vs unmasking of latent problem 821
postoperative delirium see delirium
post-stroke depression see stroke, depression after
post-traumatic stress disorder (PTSD) 641–642
bipolar disorder co-morbidity 577
chronic 641
classification 612, 640, 641
clinical features 641
delayed-onset 641
diagnosis and symptoms 614
differential diagnosis 640, 641–642
prevalence 620, 641
treatment 642
benzodiazepines 626
SSRIs 628
postural hypotension see orthostatic hypotension
potentially reversible causes of dementia
(PrD) 383
see also reversible dementias
pout reflex 133
poverty 745
depression aetiology 618
practice nurses, depression management in
ethnic groups 521, 522
Prader–Willi syndrome 691
pramipexole, depression in Parkinson’s disease 475
praxis
Alzheimer’s disease 227
assessment 132
prazosin, PTSD 642
Preadmission Screening and Annual Resident Reviews (PASARR) 792–793
precuneus, deactivation (fMRI) for memory
coding 439, 440
predementia
abnormal myo-inositol levels 282
identification by staging scales 162
markers 300
testing for/in, ethics of 410
preferred priorities of care (end-of-life) 840–841
prefrontal cortex
in AD 29
age-related increased activation 29, 439
deterioration in normal ageing 29
earlier/faster ageing of 62
episodic memory 37
executive function 132
fMRI activity, memory function 439
ventromedial, hypoactivation, in depression 492
prejudice 743
premature ageing 51–52
pre-mild cognitive impairment
Clinical Dementia Rating scale 172
see also subjective cognitive impairment (SCI)
premature infants
in SCI 845
preparedness
for SCI 845
prevalence, definition 207
prevention of mental disorders 844–849
definition 845
identifying target groups for interventions 847
indicated 845, 846
reasons for importance 844
selective 845–846
universal 845
see also individual disorders
primary depressive disorder
see also depression
primary progressive aphasia (PPA) 113
PRIME-MD 497
primary progressive aphasia (PPA) 113
primary progressive aphasia (PPA) 113
primary progressive aphasia (PPA) 113
primary progressive aphasia (PPA) 113
private psychiatric hospitals 799
private psychiatric hospitals 799
private psychiatric hospitals 799
private psychiatric hospitals 799
private psychiatric hospitals 799
private psychiatric hospitals 799
private psychiatric hospitals 799
private psychiatric hospitals 799
private psychiatric hospitals 799
private psychiatric hospitals 799
private psychiatric hospitals 799
private psychiatric hospitals 799
private psychiatric hospitals 799
private psychiatric hospitals 799
primary progressive aphasia (PPA) 113
primary progressive aphasia (PPA) 113
primary progressive aphasia (PPA) 113
private practitioners, definition 777
private psychiatric hospitals (US) 783, 796–802
admission patterns 799
description and services provided 796
discharge diagnosis 800
disorders treated 796, 800
inpatient treatment 782, 796–798
group therapy 798
length of stay 798–799
medical co-morbidity management 797
multidisciplinary team 797
multi-sensory behavioural therapy 798
neuropsychologist’s role 797–798
occupational therapist role 797
patient population 798
social worker role 797
specialised dementia units 796–797
inpatient units
adaptations used 796
structure and design 796
partial hospital programmes 799–801
example 801
PRNP gene 372, 377
codon 129 polymorphism 373, 374, 376
mutations in fatal familial insomnia 376
mutations in genetic CJD 375
P102L mutation 376
see also prion protein
pro-BACE1 290
problem-solving therapy (PST) 545
private psychiatric hospitals 799
procedural memory, training 326
professional relationships, private psychiatrists and 781–782
progeria 51–52
prognosis-based plan 811
progananul 353
gene (PGRN) see PGRN gene
progressive non-fluent aphasia (PNFA) 348
brain imaging 30, 350
clinical presentation 349
progressive supranuclear palsy (PSP) 349
observation/assessment 130
supranuclear gaze 133
subject index
prounator drift 121
propofol 199
propranolol 57–58, 629
prospective memory 62
PROSPECT trial 525, 549, 562–563
protein misfolding cyclic amplification (PMCA) 377
protein-misfolding disorders (proteinopathies) 377
psychiatrists psychiatric symptoms, physical illnesses and psychiatric services psychiatric liaison services 8 see psychiatric hospitals psychiatric history-taking see psychiatric disturbances, in elderly, ICD-10 psychiatric disorders psychiatric consultation, indications in hospital 510 psychiatric disorders see mental disorders psychiatric disturbances, in elderly, ICD-10 106 psychiatric history-taking see history-taking (psychiatric) psychiatric hospitals see hospital(s); private psychiatric hospitals (US) psychiatric intensive care units 9 psychiatric liaison services 8 psychiatric services elderly offenders 697 in long-term care in US see long-term care psychiatric symptoms, physical illnesses and cognitive impairment 122 psychiatrists collaboration with 8 income in US 779 liaison with medical/surgical teams see liaison psychiatry medical psychiatric inpatient unit 786 private practice see private practice (US) private psychiatrists’ relationship with (US) 781–782 SUBJECT INDEX in US 778, 779 in-hospital treatment and 783 see also geriatric psychiatrists psychology geriatric psychiatry as subspecialty 861 see also geriatric psychiatry overlap of medical/neurogeriatric psychiatry 788 primary care interface with 552–553 psychoactive drugs see psychotropic drugs psychoanalytic theory 636 psychogeriatricians see geriatric psychiatrists psychogeriatrics see geriatric psychiatry psychogeriatric services see geriatric psychiatry services (England) psychological changes with age 3 psychological factors as anxiety risk factor 620 depression and vascular disease link 470 psychological models/resources, successful ageing 70–71 psychological tests see neuropsychological assessment psychological therapy 543–551 access to (IAPT initiative 2007) 7, 527, 549 access to and need for further evaluation 549 adjustment disorder 642 behaviour therapy 543 bipolar disorder 583 CBT see cognitive behavioural therapy (CBT) conversion disorders 643 depression prevention 549 depressive disorders 543–549 cultural issues 526 Parkinson’s disease 474–475 post-stroke 516 development for elderly 9 dialectical behaviour therapy (DBT) 546 drug misuse treatment 683 dysthymia 549 interpersonal see interpersonal psychotherapy (IPT) mindfulness-based cognitive therapy (MBCT) 546 personality disorders 658–659 brief therapy 658 collaborative multimodal treatment 658 treatment parameters 658–659 problem-solving therapy (PST) 545 PTSD 642 reminiscence therapy and life review 549 US Medicare system and 770 psychological trauma physical symptoms due to 636, 637 see also post-traumatic stress disorder (PTSD) psychometric testing 135 psychotic disorders 602 psychometric theory 232 psychomotor changes, in depression 113 psychoneurological effects, of caregiving 831 psychoneurosis 611, 612 psychopathology, suicidal behaviour risk factor 560 psychopharmacological drugs for anxiety see anxiety; anxiolytics cross-tolerance 681–682 private practice (US) 780 see also psychotropic drugs; individual drug groups psychosexual history, in psychiatric history-taking 111 psychosocial effects, Lewy body dementias 367 psychosocial factors 543 AD risk 273 personality disorders 650 post-stroke depression 515 suicidal behaviour risk 561 prevention, strategies 561 psychotherapists personality disorder patients’ behaviour towards 659 personality disorder patients crossing boundaries 658 splitting treatment team by patient 658 psychotherapy see psychological therapy psychotic disorders (late-life) 591–608 affective disorders vs 600 classification and nosology 591–595, 597 1940–1970 592 1970–present 592 current consensus approaches 592–593 early history 591–592 clinical assessment 599, 601–603 cognitive impairment 606 development, course/duration 604 differential diagnosis of paranoid symptoms 599–601 ethnic groups/cultural differences 715 homicides 694–695 incidence/prevalence 597, 604 late-life non-affective, classification 591 late-onset 592 early-onset disorders vs 592, 593, 601 see also schizophrenia, late-onset loneliness 606 long-term care (US) 791, 793 management 602, 606 rehousing 606 offenders 696 spirituality and 742 treatment 604–608 antipsychotic drugs 604–605 CBT 605–606 compliance 604 effect on living skills/socialization 606 ethical issues 604 non-pharmacological 606 unmet need for 606 violence in 606–607 see also paranoid disorders; schizophrenia psychotic disturbances Alzheimer’s disease 229–230, 312
depression (unipolar) 496
management see antipsychotic drugs
see also delusion(s); hallucinations
psychotic symptoms
disorder differential diagnosis 599–601
disorders associated 599–601, 604
ethnic groups/cultural differences 715
PTSD 641
single, incidence/prevalences 597
psychotropic drugs
adverse outcome potential 795
cardiac effects 125, 126
geriatric psychiatrist role in long-term
care in US 790–791
monitoring 126–127
over-prescribing 100
reviews by psychiatrist in long-term care
794–795
see also drug(s); psychopharmacological
drugs; individual drug groups
public health
dementia/cognitive function decline
impact 66, 207
education, on depression awareness 526
mental illness challenges 717, 724
prevention of disorders 845
see also prevention of mental disorders
suicide prevention strategies 561
Public–Private Partnership (PPP) 748
public safety, Mental Health Act 2007 and
public health
quality of life (QoL) measures
in older age (instruments for)
methods 185–186
in older age (instruments for)
186–187
see also quality of life (QoL) measures
perceptions of 184
subjective and objective dimensions 184
quality of life assessment schedule (QoLAS)
92
quality of life (QoL) measures 183–192,
185
dementia-specific 187–188, 189
direct observational tools 185
domains and variables involved 184
generic, for older people 186–187
generic vs disease-specific 185
in health 184
in mental illness 187
proxy ratings 185
selection 188–189
self-assessment scales 185
subjective and objective dimensions 184
utility assessments (cost-effectiveness)
186
validity and reliability 184–185
variation in scales 184
Quality of Well-Being (QWB) 179, 180
self-administered (QWB-SA) 179, 180
‘Question Asking Readings’ 325
quetiapine
Alzheimer’s disease 314
bipolar disorder 582
dosage and adverse effects 313
Lewy body dementias 369
psychotic disorders 605
quinacrine, in CJD 376
race see ethnic groups
radiology 124
barium studies 124
Ramón y Cajal, S. 331–332
ramapycin 53
rapid cycling 474
classification 458
rapid eye movement sleep behaviour
disorder (RSBD; RBD) 702
rating scales 141–144
for case finding 142, 143
cut-off scores 142, 143
delivery methods 142
development 141–142
for diagnosis 143
reliability 142
scores 142
for screening 142, 143
selection 143
types/uses 143
validity 142
REACH I 418
REACH II 418
reactive nitrogen species, overproduction in
AD 292
reactive oxygen species
DNA damage 53
overproduction, in AD 292
reading
difficulties, Alzheimer’s disease 227
semantic dementia 349
testing 132, 136
reality orientation 326
receptive dysphasia 113
recognition memory, assessment 390
Record of Independent Living (RIL) 179, 180
recruitment of geriatric psychiatrists, in US
858
‘reduced reserves’ in old age 117
reelin 293
re-feeding syndrome 826
regeneration of ageing brain 42–44, 333
see also neurogenesis
regenerative medicine
in AD 331
advanced therapies 334–338
clinical trial design 337
diseases appropriate for 337
drugs approved (FDA) 337–338
historical background 330–331
in Huntington’s disease 331
in Parkinson’s disease 331
see also gene therapy; neural stem cells
(NSCs); neural transplantation
regenerative sprouting 42, 43
Regional Health Authorities (RHAs) 747
regulated intramembrane proteolysis (RIP)
289
rehabilitation 810–816
alcohol abuse 667
assessments for 811
attitudes to 814
definition 810
developing themes in 813–814
drug misuse 683
funding issues 812, 813
goals 810, 811, 813
long stay care and 812–813
neurorehabilitation, in dementia 813
NHS continuing care focus on 760
people and facilities aiding 811–812
person-centred care 813
planning 811
principles (in psychiatric disorders)
810–812, 814
prognosis-based plan 811
special problems with psychiatric
disorders 810
rehousing, psychotic disorders 606
rejection, fears of 709
relationships
depression impact on 546
doctor–patient see doctor–patient
relationship
family see families
pre-bereavement 555, 556
professional 781–782
quality
Dementia Care Mapping evaluating
158
disability affecting, rehabilitation and
811
pre-bereavement 555–556
spousal and well-being 464
supportive see supportive relationships
therapeutic 659
relaxation techniques 406
reliability
Clinical Dementia Rating (CDR) 170
172
Dementia Care Mapping (DCM)
158–159
single photon emission computed tomography (SPECT) continued
bipolar disorder 578
clinical protocol 257
Lewy body dementias 366
memory impairment and 257–258
PET comparison 257, 259
principle and image acquisition 257
radioligands 257
spatial resolution 257
SIRT gene 52
Sjögren’s syndrome, investigations 124
Skill-Based Objectives in Old Age Psychiatry (2002) 861
social care 814
social adversity, depression aetiology 618
Social Adaptive Functioning Evaluation 179, 180
social activities
age-related changes 700
efficiency (SE) 701
NREM 700, 701, 702
phase advances 701
questionnaires 703
regulation and circadian rhythms 700
REM 700, 701
research, future directions 703–704
slow wave 700, 701
stages 700
studies/investigations 127
sleep-disordered breathing (SDB) 703
sleep disorders 700–705
apnoeas and hypopnoeas 703
breathing disorders 703
consequences 700
insomnia see insomnia
movement disorders 702
REM sleep behaviour disorder (RSBD; RBD) 365, 702
sleep disturbances
dementia and AD 230, 703
Lewy body dementias 365
sleep electroencephalogram 569
sleep history 701
sleep induction drugs 701
OBRA Interpretive Guidelines 794
sleepiness, daytime 703
sleep-related breathing disorders 703
sleep-related movement disorders 702
S-MAST-G 667, 673
smoking, dementia risk and 210, 272
SNCA gene 367
’Snoezele’ units 798
snoring 703
social activities
importance 99–100
limited
depression and 618
long stay care patients 813
Social Adaptive Functioning Evaluation (SAFE) 179, 180
social adversity, depression aetiology 618
social care 814
social constructs, somatoform presentation reflecting 638
social decline, alcohol abuse and 666–667
social factors, in mental health 97–101
as anxiety risk factor 620
causal relationship 97–98
coping abilities and life events 97, 98, 465, 466
life course perspective 97, 98, 464, 465
mental disorder treatment affected by 99
mental health influencing relationships 97
social engagement/activities importance 99–100
social selection of mental disorders 97, 98
social support role 98, 100
social functioning
in daily living skills 177
successful ageing 70
social history, in psychiatric history-taking 111
social insurance 770
social interventions, simulated, in AD management 325
social isolation, late-onset schizophrenia 601, 604
socialization, CBT effect in psychotic disorders 606
social needs
care homes 761
in learning disability 691–692
NHS continuing care 761–762
social networks
depression inversely associated 719
diverse or restricted, well-being and 466
gender differences 719
size reduced with age 466, 719
see also social support; support network
social policies 99
Social Skills Performance Assessment (SSPA) 179, 181
social support
in AD 325
in affective disorders 465
coping abilities and 464, 465
depression management 525
for family caregivers 417
gender difference in 618
importance/role 98, 100
lacking, depression associated 98, 520, 618, 719
in mental disorders 98, 464, 465, 466
suicide prevention 562
for widows/widowers 845
for women, resource deficits and 466
see also social networks; supportive relationships
social withdrawal, sexual activity problems leading to 74
social workers
gerontological, in US 857
role in private psychiatric hospital 797
socioeconomic disadvantage, depression prevalence 718–719
socioeconomic status, coping behaviours 465
solvent exposure, long-term, dementia associated 380
somatic cell therapy 330–341
definition 334
somatization 636, 638
cultural differences, emotional distress 714
depression and 495, 508, 521, 524
South Asia 731
in general hospitals 806–807
management 511
somatization disorder 636
somatoform disorders 636–639
classification 636
clinical presentations 636–637
conversion disorders vs 643
diagnostic features 613, 614
epidemiology 637
in general hospitals 806–807
outcomes 638
personality disorders vs 657
treatment 638
somatopause 45–46
somatostatin 45–46
in AD 296
South America, depression prevalence 483
South Asia, mental illness 730–734
care arrangements for elderly 731–732
dementia as hidden problem 730
dementia diagnosis/screening 730
dementia prevalence 719, 721, 722, 730
vascular dementia vs AD 719, 730
depression 731
resource limitation for care 731
South Asians (in UK), depression attitudes to seeking help for 520, 521, 522
barriers to care for 518, 519, 522
concepts and causation 520
diagnosis and symptoms 525
facilitators to care 519–520
family as source of help 520
somatization/medicalization 521
South East Asia, vascular dementia and AD prevalence 719, 730
spaced retrieval 326, 398
spatial perception ability, testing 392
speech
assessment 391
content 131
fluent 132
in Mental State Examination (MSE) 113–114
non-fluent 132
Alzheimer’s disease 227
perseverative 113–114
in physical examination 118
poverty of 113
pressure of 113
progressive non-fluent aphasia (PNFA) 349
semantic dementia 349
see also language
spirituality 741–744
coping strategies, for depression 518, 520
definitions 741
dementia and 742
depression and psychosis 742
health benefits 741
stress process model 415
stress reduction techniques 406
stroke
alcohol use and 675
dementia 342
clinical course 343
epidemiology 343–344
IQCODE prediction of 149
pathogenesis 344
time of onset 343
see also vascular dementia (VaD)
depression after 468, 515–517, 552, 567, 569, 619, 719
diagnosis 515
left-sided vs right-sided stroke 567
prevalence 515
prevention 516
treatment 516
depression as risk factor of 469, 567
ECT after 531
lesion location, depression association 515, 567
mania after 574
manic precipitated by 574
meningovascular neurosyphilis vs 428
neurogenesis after 334
prevalence, in China 737
prevention 345
risk factors 344
depression 469, 567
risperidone causing 58
see also cerebrovascular disease
Stroop color-word interference 491
Stroop Color Word test 21, 392, 491
structural changes (brain)
macrostructural 17, 36
microstructural 18
Structured Interview for Disorders of Personality scale (SIDP-R) 651, 655
structure–function correlations, MRI, normal ageing 17
Study of Health and Retirement in Europe (SHARE) study
subcortical–cortical pathway disconnection 344
subcortical dementia 233
subcortical hyperintensities, mania 574
subcortical lesions, alcoholic dementia 378
subcortical syndromes, observation in 130
subdural haematoma (SDH) 384
reversible dementia 385, 386
subgranule layer (SGL) of dentate gyrus, neurogenesis 291, 332
subjective cognitive impairment (SCI) 164
Functional Assessment Staging (FAST) 167
GDS scale 163, 164
time course 163
see also pre-mild cognitive impairment
substance abuse 679
by abusers of the elderly 836
bipolar disorder co-morbidity 577
definitions 679, 680
mood disorders due to 566
see also alcohol abuse; drug misuse
Substance Abuse and Mental Health Services Administration (SAMHSA) 177, 774
substances of abuse 679
dementia associated 380
substantia nigra, mitochondrial mutations 53
substituted judgement standard 411
subsyndromal depression (SSD) 498, 566
subventricular zone (SVZ) changes, olfaction impairment 334
neurogenesis 291, 332
thickening in Huntington’s disease 334
thinning in Parkinson’s disease 334
successful ageing 70–73
biomedical theories 71
definition 70, 72
good self-rated health correlation 71, 72
lay definitions/views 70, 71–72
multidimensional models 70
parameters, associations between pairs 72
psychological models/resources 70–71
Ryff’s theoretical model 71
see also normal ageing
suicidal behaviour 559–564
Alzheimer’s disease and 560, 561, 806
deterrents 562
hospitalization for 562
hospitalization outcomes 563
management 562–563
risk factors 559–561
adulthood factors 560
biological factors 561
demographic factors 559
early life factors 559–560
late life factors 560–561
physical health/disability 560–561
prevalence 559–561
psychopathology 560
psychosocial factors 561
suicidal ideation 563
in depression 497, 512, 560
prevalence 559
religions views affecting 742
suicide
acceptability, different ethnic groups 714–715
after homicide 695
attempted, decline in rates with age 559
depression see depression (geriatric), suicide
methods, China 739
prevention strategies 561–563
indicated prevention 562–563
selective prevention 561–562
universal prevention 561
rates 559, 806
China 739–740
depression, in South Asia 731
religions views 742
risk 559
in depression 500
reduced with spiritual beliefs 741
risk assessment 562
‘sundowning’ 703
subjective dismutation 282
superoxide dismutase 3 gene 53
Supervised Community Treatment (SCT) 852
support groups, family caregivers 418–419
supportive relationships 98, 464, 465
dementia patients in care homes 80
in mental disorders 98
see also social support
support network
activation difficulty in depression 464–465
patients of US private practice 781
see also social networks
support-orientated track, private psychiatric hospitals (US) 799
support services
family caregivers 418–419, 831–832
in rehabilitation 811
suprachiasmatic nucleus (SCN) 48, 300, 700
sleep disturbances in AD 703
supraneural gaze 133
‘surface dyslexia’ 349
surgical teams, liaison with mental health teams see liaison psychiatry
surrogates, decision making 411, 412, 769
surveillance, dementia patients 413
surrogates, decision making 411, 412, 769
syndrome of inappropriate antidiuretic hormone (SIADH) 122, 123
α-synuclein 360
deposition, pathogenesis 363, 365
gene mutation, Parkinson’s disease 127
gene triplication 367
Lewy body dementia aetiology 363
α-synucleinopathies see Lewy body dementia spectrum
synucleinopathy, early, REM sleep behaviour disorder 702
syphilis
investigations 124, 428
neurosyphilis 384, 428
ocular 428
treatment 428
Systematic Treatment Enhanced Program for Bipolar Disorder (STEP-BD) 580, 583
systemic lupus erythematosus (SLE) 124

TAR DNA-binding protein 43 (TDP-43) 348, 351, 352
task simplification 326
tau 287, 292, 351
anaesthetic effect 822
antibodies 253
conditional transgenic mouse model 253, 254
FTD variants with/without 351–353
haptotype H1 and H2 282
hyperphosphorylation 240, 252, 287, 291–292, 352
GSK3 association 292
inclusions 252
increased in AD 300
isoforms 252
mutations 254
frontotemporal dementia 127
normal ageing and MCI 295
phosphorylation genes regulating 282
signalling cascade regulating 293
sites, and enzymes 292
see also neurofibrillary tangles
tau kinase, inhibitors 309
tauopathies 108, 352
transgenic mouse models 252–253
see also frontotemporal dementia (FTD) syndromes
TCAs see tricyclic antidepressants
TDP-43 348, 351, 352
technetium-99m labelled ethylcysteinate dimer (99mTc-ECD) 257
technetium-99m labelled hexamethylpropyleneamine (99mTc-HMPAO) 257
Tele-Check 562
Tele-Help 561–562
telomere sequences, shortening 52
temazepam, pharmacodynamics 58
temporal arteritis 700
temporal lobe atrophy, in MCI vs AD 266, 267
Temporal Orientation Test (TOT) 389
temporoparietal cortex, in AD 29
Test of Everyday Attention 137
testosterone, age-related changes in levels 46–706, 708
in women 706
test-retest reliability 142
MMSE 145
‘tet-off system’ models 254
terapy of mind 349
therapeutic alliance, personality disorders 659
therapeutic drug monitoring 126, 537
therapeutic nihilism 525
therapeutic relationship, personality disorders 659
thermoregulation, impairment 58
thiamine 379
deficiency 378, 379
replacement 826
thiazide diuretics, lithium interactions 581
thioridazine, in Alzheimer’s disease 314
thought in Alzheimer’s disease 227
challenging, in CBT 544
content and form 114
in Mental State Examination (MSE) 114
thought diary 544, 545
thiouracil antibodies 47
thyroid dysfunction, reversible dementia 384
thyroid function testing (TFT) 124
thyroid hormones 384
age-related changes 47
thyroid-stimulating hormone (TSH) 47
thyrotrophin-releasing hormone (TRH) 47
thyroxine (T4) 47
TOR pathway 53, 54
‘total pain’ 839
total sleep time (TST) 701
Tourette’s syndrome 632
traditional healers 715
training
career choice 860
doctors 748
geriatric psychiatrists 814, 860–863
consensus curriculum 861
postgraduate schools 862
recent developments 860–861
geriatric psychiatrists in Canada 861, 862
geriatric psychiatrists in UK 8–9, 854–856, 860
advanced training 855
content, assessment and appraisal 862
continuing professional development 855–856
core training 855
development/growth as specialty 854
duration 854, 855
formative/summative assessments 862
lifelong learning 856
postgraduate education 854
postgraduate schools 862
undergraduate teaching 854
geriatric psychiatrists in US 857–859, 860, 861, 862
ACGME program requirements 857–858
funding for studies on 858
incentives 858
mentorship 858
liaison psychiatry 804–805
on nutrition 827
provision 860–861
see also education
tranquilizers
misuse 682
see also antipsychotic drugs; anxiolytics
transcranial magnetic stimulation (TMS) 37
repetitive see repetitive transcranial magnetic stimulation (rTMS)
thalassemia 377
transferrin
alpha-1 antitrypsin deficiency 667
decline in AD 301
TfC2, as antemortem marker 301
transgenic mice see mouse models
transient ischaemic attack, risperidone causing 58